Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 3 of 102 
  
Investigator Agreement:   
I have read the protocol and agree to conduct the study as outlined herein. 
 
 
Signature: __________________________________ Date: ______________  
Name 
(print):    
    
 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1227996] OF ABBREVIATIONS .........................................................................................14  
3.0 BACKGROUND AND RATIONALE ...........................................................................16  
3.1 Medical Background and Brief Rationale for the Trial .........................................16  
4.0 CLINICAL TRIAL OBJECTIVE AN D CLINICAL HYPOTHESIS ........................17  
4.1 Clinical Trial Objective ..........................................................................................17  
4.2 Clinical Hypothesis ................................................................................................17  
5.0 STUDY DESIGN ..............................................................................................................18  
5.1 Study Duration .......................................................................................................20  
6.0 SELECTION AND DISPOSITION OF SUBJECTS ...................................................20  
6.1 Number of Subjects................................................................................................20  
6.2 Clinical Trial Populat ion Characteristics ...............................................................20  
6.2.1  Inclusion Criteria ...................................................................................20  
6.2.2  Exclusion Criteria..................................................................................21  
6.3 Previous and Concomitant Therapi[INVESTIGATOR_014] ....................................................................22  
6.3.1  Definitions .............................................................................................22  
6.3.2  Categories ..............................................................................................23  
6.3.3  Authorized Concomitant Therapi[INVESTIGATOR_014] ......................................................23  
6.3.4  Prohibited Concomitant Therapi[INVESTIGATOR_014] ........................................................23  
6.3.5  Procedures/Reasons for Subject Discontinuation/Withdrawal .............[ADDRESS_1227997] Identific ation Number ..............................................................26  
7.1.2  Method of Treatment Assignment and Blinding ...................................27  
7.1.3  Study Medication Kit Number ..............................................................27  
7.1.4  Instructions for Use and Admi nistration of Adapalene 0.3% / 
Benzoyl Peroxide 2.5% Gel ..................................................................27  
7.1.5  Instructions for Use and Admini stration of Doxycycline Hyclate ........27  
7.1.6  Dose Modification .................................................................................28  
7.1.7  Other Supplies .......................................................................................28  
7.2 Investigational Study Drug Packaging and Labeling .............................................28  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 5 of 102 
 7.3 Supplies Management ............................................................................................28  
7.3.1  Study Medication Accountability .........................................................28  
7.3.2  Study Medication Storage .....................................................................29  
7.3.3  Study Medication Dispensing and Return ............................................29  
7.4 Treatment Compliance Mana gement and Records ................................................30  
8.0 STUDY ASSESSMENTS AND PROCEDURES ..........................................................30  
8.1 Efficacy Assessments .............................................................................................30  
8.2 Efficacy Measurements ..........................................................................................30  
8.2.1  Investigator’s Global Assessment (IGA) ..............................................30  
8.2.2  Lesion Counts .......................................................................................31  
8.2.3  Oral Isotretinoin Evaluation ..................................................................31  
8.3 Safety Assessments ................................................................................................32  
8.4 Safety Measurements .............................................................................................32  
8.4.1  Local Tolerability Assessment ..............................................................32  
8.4.2  Adverse Events .....................................................................................34  
8.5 Other Assessments .................................................................................................38  
8.5.1  Facial Photographs (Canfield Scie ntific Manual of Procedures) ..........[ADDRESS_1227998]’s Assessment of Acne Improvement ........................................38  
8.5.3  Dermatology Life Quality Index (DLQI™), Children’s 
Dermatology Life Qualit y Index (cDLQI™) .......................................[ADDRESS_1227999] Satisfaction Questionnaire .......................................................39  
8.5.5  Acne-Specific Quality of Life  Questionnaire (Acne-QoL) ...................39  
8.6 Appropriateness of Measurements .........................................................................40  
9.0 CLINICAL TRIAL VISITS ............................................................................................40  
9.1 Description of Clini cal Trial Visits ........................................................................40  
9.1.1  Screening Visit ......................................................................................40  
9.1.2  Baseline Visit ........................................................................................41  
9.1.3  Week 4 Visit (± 3 days) ........................................................................43  
9.1.4  Week 8 Visit (± 3 days) ........................................................................44  
9.1.5  Week 12/Early Termination Visit (± 3 days) .........................................45  
9.2 Additional Instructions for Subjects ......................................................................46  
10.0 PLANNED STATISTICAL ANALYSES AND STATISTICAL CONSIDERATIONS .......................................................................................................46
 
10.1 Statistical Analysis Plan .........................................................................................46  
10.2 Sample Size Determination ....................................................................................46  
10.3 Analysis Populations ..............................................................................................47  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228000] of the Clinical Trial .....................................................................49  
11.3 Informed Consent...................................................................................................49  
11.4 Contractual Requirements ......................................................................................50  
12.0 REGULATORY/ADMINISTRATIVE PROCEDURES AND 
DOCUMENTATION .......................................................................................................50  
12.1 Quality Assurance and Audits/Inspections ............................................................50  
12.2 Protocol Compliance and Protocol Deviations ......................................................50  
12.3 Protocol Amendments ............................................................................................50  
12.4 Data Collection and Electronic Case Report Forms (eCRFs) ................................51  
12.5 Source Documentation ...........................................................................................51  
12.6 Study Initiation and Personnel Training ................................................................51  
12.7 Clinical Monitoring ................................................................................................51  
12.8 Data Management ..................................................................................................52  
12.9 Study Documentation and Retention of Records ...................................................52  
12.10 Insurance ................................................................................................................52  
13.0 REFERENCES .................................................................................................................53  
14.0 APPENDICES ..................................................................................................................56  
14.1 PACKAGE INSERTS FOR ADAPALEN E 0.3% / BENZOYL PEROXIDE 
2.5% GEL AND DOXYCYCLINE HYCLATE TABLETS .................................56  
14.2 PROCEDURE FOR FACIAL LESION COUNTS ...............................................88  
14.3 DERMATOLOGY LIFE QUALITY INDEX (DLQI™) ......................................90  
14.4 CHILDREN’S DERMATOLOGY LIFE  QUALITY INDEX (cDLQI™) ............[ADDRESS_1228001] SATISFACTION QUESTIONNAIRE ................................................94  
14.6 ACNE-SPECIFIC QUALITY OF  LIFE QUESTIONNAIRE ...............................96  
14.7 DECLARATION OF HELSINKI..........................................................................99  
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228002] OF TABLES 
 
Table 1. .................  Schedule of Study Assessments .......................................................................19  
Table 2. .................  Exit Form Reasons for Discontinuation ...........................................................25  
Table 3. .................  Description and Dispensi ng of Study Medications ..........................................26  
Table 4. .................  Investigator’s Global Assessment Severity Scale ............................................[ADDRESS_1228003]’s Assessment of Acne Improvement Scale .........................................39  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 8 of 102 
 1.0 PROTOCOL SYNOPSIS 
TITLE OF 
STUDY EFFICACY AND SAFETY OF ADAPALENE 0.3% / BENZOYL PEROXIDE 2.5% GEL PLUS DOXYCYCLINE IN SEVERE 
INFLAMMATORY ACNE (NON-NODULOCYSTIC) SUBJECTS 
STUDY CENTERS No more than 25 sites 
PHASE  4 
STUDY OBJECTIVE Demonstrate that a daily treatm ent regimen of adapalene 0.3% / 
benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is an effective 
and safe alternative to oral isotretinoin in severe inflammatory acne with less than 3 nodules or cysts (non-nodulocystic) during a 12-week 
treatment period. 
STUDY DESIGN This is a Phase 4, 12-week, single-arm, open-label, multi-center investigational study in subjects with severe inflammatory acne. 
Male and female subjects, [ADDRESS_1228004] up to 2 nodules on 
the face, are evaluated wi th a score of 4 (severe) on the IGA scale, and 
who in the opi[INVESTIGATOR_878932], are to be enrolled. 
Up to 25 independent study centers will participate in the study, and 
approximately 180 subjects will be enrolled. Subjects who meet the inclusion criteria and none of the exclusion criteria at the Screening 
visit will return to the clinic on Week 0 for baseline measures and to start treatment which will continue for a period of up to 12 weeks.  
Subjects who do not need to undergo a wash-out period ( Section 6.2.2 ) 
may combine the Screening visit an d Baseline visit and thus attend 4 
clinic visits. Screened subjects re quiring a wash-out period (up to 4 
weeks) prior to baseline measurements and beginning treatment will 
attend a total of 5 visits. 
Following the Baseline (Week 0) visit, all subjects will report to the 
clinic for efficacy and safety evaluations at Weeks 4, 8, and 12. 
Subjects will be provided with Cetaphil Gentle Skin Cleanser and 
Cetaphil Daily Facial Moisturizer SPF15  throughout the study to help 
minimize potential irritation. 
PLANNED SAMPLE SIZE Approximately [ADDRESS_1228005] SELECTION CRITERIA Inclusion Criteria:  
1. Male or female subjects, 12 years of  age or older at Screening visit.

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 9 of 102 
 2. Subjects with a clinical diagnosis of severe inflammatory acne 
(IGA score of 4) who, in the op inion of the Investigator, are 
candidates for oral isotretinoin at Screening and Baseline. 
3. Subjects with ≤ 2 nodules on the face, < 1 cm in diameter. 
4. Subjects willing to be photographed at study visits. Photographs may be used for research, marketing, promotional, and/or scientific purposes. 
5. Female subjects of child-bearing potential able and willing to use a highly effective method of contrace ption associated with a barrier 
form of contraception from one month before beginning treatment 
to one month after treatment discontinuation.  
A highly effective method of contra ception is defined as: bilateral 
tubal ligation; combined oral contraceptives (estrogens and 
progesterone) or implanted or injectable contraceptives with a stable dose for at least 1 mont h prior to baseline; hormonal 
intra-uterine device (IUD) insert ed at least 1 month prior to 
baseline; vasectomized partner for at least [ADDRESS_1228006]. 
Barrier forms of contraception include diaphragms, latex condoms, and cervical caps; each must be used with a spermicide. 
*For minors not yet sexually active, abstinence is an acceptable form of birth control. 
6. Subjects able to follow instructi ons and likely to complete all 
required visits. 
7. Subjects [ADDRESS_1228007] one 
parent or guardian r ead and sign the Informed  Consent Form prior 
to any study-related procedure. (T he parent or guardian is not 
required to attend the followi ng visits unless requested.) 
Exclusion Criteria:  
1. Subjects with nodulocystic or cong lobate acne, acne fulminans, or 
secondary acne (chloracne, drug-induced acne, etc.). 
2. Subjects with ≥ [ADDRESS_1228008] used any systemic therapy directed at 
improving acne, including antibiotics, within 30 days prior to 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228009] received topi[INVESTIGATOR_878933]: 
a. Hydroquinones, peels, photody namic therapy, laser therapy, 
microdermabrasion, deep chemic al peel, or plastic surgery 
within 4 weeks prior to baseline. 
b. Corticosteroids, antibiotics, antibacterials, antiseptics, 
retinoids, azelaic acid, dapsone, other anti-inflammatory drugs, other acne treatments, or light therapy within 2 weeks 
prior to baseline. 
c. Zinc-containing products, or co smetic procedures (facials, 
comedone extractions, etc.) within  [ADDRESS_1228010] received systemic treatment by [CONTACT_13216], antibiotics, or spi[INVESTIGATOR_878934] 4 weeks prior to baseline. 
Note: No washout period is requir ed for oral vitamin A up to the 
recommended daily dose (4000 - 5000 IU).  
8. Subjects who have started taking medications to treat a concurrent 
medical condition for which the type  and dose has not been stable 
in the opi[INVESTIGATOR_878935] 90 days prior to 
signing the Informed Consent Form and/or is expected to change 
during the course  of the study. 
9. Subjects with a condition or circumstance which, in the Investigator’s opi[INVESTIGATOR_1649], may put the subject at risk  (e.g., a history 
of significant renal disease with impairment of renal function), 
confound the study results, or in terfere with the subject’s 
participation in the study. 
10. Subjects who are at risk in te rms of precautions, warnings, and 
contraindications for the i nvestigational study drugs (see 
Appendix 14.1 for package inserts for adapalene 0.3% / benzoyl peroxide 2.5% gel and doxyc ycline hyclate tablets). 
11. Subjects with a known allergy to any of the components of the 
study products and/or a known hype rsensitivity to adapalene, 
benzoyl peroxide, and/or tetr acycline class antibiotics. 
12. Subjects with a skin condition which,  in the Investigator’s opi[INVESTIGATOR_1649], 
may interfere with study assessments. 
13. Subjects who will be exposed to intensive ultraviolet (UV) radiation during the study (mount ain sports, sunbathing, tanning 
beds, etc.). 
14. Subjects who have participated in an interventional investigational 
study within 30 days of signing the Informed Consent Form, 
participated in biologic investig ational studies within 90 days of 
signing the Informed Consent Form, or who plan to participate in any other interventional clinical research study while participating 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228011] access to  the clinical study protocol.  
TREATMENTS Investigational Study Drugs: 
 Topi[INVESTIGATOR_112934] 0.3% / benzoyl peroxide 2.5% emulsion gel (one 
application daily for 12 weeks) 
 Oral doxycycline hyclate, 200 mg pe r day (two 50-mg tablets twice 
daily for 12 weeks)  
Non-investigational Study Products: 
 Cetaphil Gentle Skin Cleanser (twice daily) 
 Cetaphil Daily Facial Moisturize r SPF15 (at least once daily, and 
as needed) 
EFFICACY 
PARAMETERS  Efficacy parameters to be assessed at Weeks 4, 8, and 12: 
 Investigator’s Global Assessment (IGA) 
 Inflammatory and Non-inflammatory Lesion Counts 
EFFICACY ASSESSMENTS  Investigator Global Assessment: Evaluates acne severity on 0-4 
scale 
 Lesion Count: Enumerates inflammatory and non-inflammatory 
lesions 
 Oral Isotretinoin Evaluation: Dete rmines if, in the opi[INVESTIGATOR_684], the subject is a candidate for or al isotretinoin 
EFFICACY 
ENDPOINTS Primary efficacy endpoint: 
 Reduction in number of inflam matory lesions at Week 12 
Secondary efficacy endpoints: 
 IGA Success Rate at Weeks 4, 8, and 12 
 Percent reduction in total, infl ammatory, and non-inflammatory 
lesions at Weeks 4, 8, and 12 
 Number and percent of subjects  who, in the opi[INVESTIGATOR_684], are candidates for oral isotretinoin at Weeks 0, 4, 
8, and 12 
 Reduction in number of total, inflammatory, and non-inflammatory 
lesions at Weeks 4, 8, and 12 
 Subject Assessment of Acne  Improvement at Week 12 
SAFETY 
PARAMETERS Safety parameter to be assessed for all subjects at Baseline and at every subsequent visit: 
 Incidence of Adverse Events (AEs) 
SAFETY ASSESSMENTS  Adverse Events: En umeration and details of all AEs 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 12 of 102 
  Local Tolerability: Measur es of erythema, scali ng, drying, and 
stinging/burning on a 0-3 scale 
STATISTICAL 
ANALYSES Analysis Populations:   
The Intent-to-Treat (ITT) Population consists of the entire population 
enrolled at baseline. All efficacy data will be analyzed for the ITT 
Population.   
The Safety Population consists of th e ITT Population after exclusion of 
subjects who never took the treat ment with certainty, based on 
monitoring reports. All safety analyses will be summarized for the 
Safety Population. 
General Statistical Methods: 
All efficacy variables will be summar ized at each visit for the ITT 
Population. Categorical variables wi ll be summarized by [CONTACT_878963] (N, %). Continuous variables 
will be summarized using number of subjects, means, standard 
deviations (SD), medians, minimu ms, and maximums for the data 
collected at each visit. Confidence in tervals (CI) will be presented as 
appropriate. All evaluations (inc luding CIs) will be reported for 
exploratory purposes and will be interpreted as such. No formal statistical tests will be performed. 
Subject demographics and baseline characteristics will be summarized 
with descriptive statistics. Subject  disposition will be summarized 
with the number of subjects in th e Safety Population, the number and 
percentage of subjects who complete the study, and the number and percentage of subjects who do not complete the study for each discontinuation reason.  
The primary endpoint is the reductio n in the number of inflammatory 
lesions at Week 12, and is the ch ange in the lesion count from 
Baseline to Week 12. The reduc tion in lesion count will be 
summarized with descriptive statistics, with a 95% CI for the 
reduction in lesions.  
The IGA Success Rate is defined as the number and percent of 
subjects rated as Clear (Grade 0) or Almost Clear (Grade 1), and will be summarized at Weeks 4, 8, and 12 with a 95% CI for the Success Rate. The number and percent of subj ects who are candidates for oral 
isotretinoin will be summarized at Weeks 0, 4, 8, and 12, with a 95% 
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228012] (LOCF) approach 
will be used as a sensitivity analysis. 
Exposure to investigational st udy drugs and compliance will be 
summarized using descriptive statistics. AE terms will be coded using 
the Medical Dictionary for Re gulatory Activities (MedDRA). 
Incidence of treatment-emergent AEs will be summarized by [CONTACT_11189] (SOC) and preferred term (PT) for the Safety Population. Additional summa ry tables will be provided for 
AEs considered related to the investigational study drug, and for AEs leading to discontinuation. 
The symptoms of local tolerability (erythema, scaling, dryness, and 
stinging/burning) will be summarized by [CONTACT_878964].  
Complete listings of all data repr esented on the electronic case report 
form (eCRF) will be provided as an appendix to the final study report 
to facilitate further i nvestigation of tabulated values and to allow for 
clinical review of all parameters. 
FINAL DATE Version 1.0 28 JUN 2016 
 
 
  
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228013] OF ABBREVIATIONS 
Abbreviation or Term Definition/Explanation 
AE Adverse Event 
BPO Benzoyl Peroxide (C14H10O4) 
CDMS Clinical Data Management System 
CI Confidence Interval 
CRA Clinical Research Associate 
CRO Contract Research Organization 
DMP Data Management Plan 
eCRF Electronic Case Report Forms 
EDC Electronic Data Capture 
e.g. For Example (Latin: exempli gratia ) 
ET Early Termination 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
HIPAA Health Insurance Portabilit y and Accountability Act of 1996 
ICF Informed Consent Form 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IGA Investigator’s Global Assessment 
IND Investigational New Drug 
IRB Institutional Review Board 
ITT Intent-To-Treat 
IUD Intrauterine Device 
LOCF Last Observation Carried Forward 
MCID Minimal Clinically Important Difference 
MD Medical Doctor 
MedDRA Medical Dictionary  for Regulatory Activities 
N or n Number 
N/A Not Applicable 
OTC Over-the-Counter 
CCI
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 15 of 102 
 Abbreviation or Term Definition/Explanation 
PT Preferred Term 
PV Pharmacovigilance  
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SIN Subject Identification Number 
SOC System Organ Class 
SOP Standard Operating Procedure 
SPF Sun Protection Factor 
UPT Urine Pregnancy Test 
US [LOCATION_002]  
UV Ultraviolet 
WHO World Health Organization 
 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 16 of 102 
 3.0 BACKGROUND AND RATIONALE 
3.1 Medical Background and Brief Rationale for the Trial 
Acne vulgaris is a chronic inflammatory dise ase affecting approximately 80% of young adults 
and adolescents.1-4 Four main pathogenic factor s are known to lead to its  development: follicular 
hyperkeratosis, increased sebaceous gland activity with hyperseborrhoea, microbial 
hypercolonization with Propi[INVESTIGATOR_76494] ( P. acnes ), and inflammation and 
immunological host reaction. The traditional acne treatment paradigm is directed toward these 
factors: initial treatment is with topi[INVESTIGATOR_878936], followed by [CONTACT_878965] (preferably 
combined with topi[INVESTIGATOR_12450]), and hormonal tr eatment in women. For management of severe 
nodulocystic acne that has been proven unresponsiv e to these conventiona l therapi[INVESTIGATOR_014], including 
systemic therapy, the treatmen t of choice is isotretinoin.5-7 
Isotretinoin (13-cis-retinoic acid ), an isomer of retinoic acid, wa s first introduced as a treatment 
for acne vulgaris and various other skin disorders in  the 1980s. In the last decade, it is estimated 
that over 11.[ADDRESS_1228014] been dispensed worldwide; 81 million grams of isotretinoin were dispensed from 2000 th rough 2009 (IMS Health, MIDAS Database, MAT 
Dec 2000–MAT Dec 2009).
8,[ADDRESS_1228015] known teratogens among pres cription medications, with the 
overall risk of birth defects estimated to be up to 30%. In addition, by [CONTACT_878966], it produces a patte rn of significant adverse effects similar to 
that seen in hypervitaminosis A. Side effect s have been observed in the mucocutaneous, 
musculoskeletal, ophthalmic, and central nervous systems.14,16-[ADDRESS_1228016] the use of isotretinoin 
for less severe forms of acne is emerging. Therefor e, there is a growing n eed for an alternative 
safe and effective treatment for acne vulgaris.  
A medication which can help meet this need is  Adapalene-Benzoyl Peroxide (C14H10O4; BPO) 
gel, a unique antibiotic-free combination of ad apalene 0.3%, a well-tolerated and efficacious 
topi[INVESTIGATOR_1832], and BPO 2.5%, a well-established an timicrobial agent. The complementary 
modes of action, and the positive efficacy and sa fety profiles of these two agents, make 
adapalene-BPO gel the most logical choice for once- daily treatment for all types of acne but the 
most severe. Adapalene possesses anticomedoge nic, comedolytic, and anti-inflammatory 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228017] P. acnes.25,26 Because 
neither retinoids nor BPO create selective pressure for resistan ce, this combination may be 
expected to decrease the incidence of epi[INVESTIGATOR_878937].27 
Adapalene-BPO gel has been evaluated in clinic al trials as a treatment for acne, and has 
demonstrated significant efficacy in  several large clinical studies.28-30 As a result, adapalene-
BPO gel has been granted marke ting authorization in Canada unde r the trade name [CONTACT_878987]® 
(Galderma). It has also been shown that ad apalene-BPO provides higher efficacy when more 
lesions are presented at baseline.[ADDRESS_1228018] alternative.36,37  
The gel formulation of adapalene 0.3% / benzoyl peroxide 2.5% (see Appendix 14.[ADDRESS_1228019] insert) has been shown to be effective and safe, and represents a more potent 
combination product to treat  severe acne vulgaris. 
The overall objective of this Phase 4 trial is to  determine the extent to which daily treatment 
with adapalene 0.3% / benzoyl peroxide 2.5% ge l plus oral Doxycycline [ADDRESS_1228020] s (non-nodulocystic/non-
conglobate). 
4.0 CLINICAL TRIAL OBJECTIVE AND CLINICAL HYPOTHESIS 
4.1 Clinical Trial Objective 
The clinical trial objectiv e is to demonstrate that a daily tr eatment regimen of adapalene 0.3% / 
benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is an effective and safe alternative to oral 
isotretinoin in subjects 12 years of age and older having severe inflammato ry acne with less than 
3 nodules or cysts (non-nodulocystic/non-cong lobate) during a 12-w eek treatment period. 
4.2 Clinical Hypothesis 
The proposed clinical efficacy hypothesis is base d on the current Acne Treatment Guidelines for 
severe inflammatory acne from the American Academy of Dermatology/American Academy of 
Dermatology Association.37,38  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228021]-line ther apy for severe inflammatory acne is an oral 
antibiotic + topi[INVESTIGATOR_878938] (BPO) + Antibiotic or 
Retinoid + BPO or Retinoid + BPO + Antibiotic. Thus, daily combination therapy with 
adapalene 0.3% / benzoyl peroxide 2.5% gel and Doxycycline [ADDRESS_1228022]-
line therapy for severe inflammatory  acne; the hypothesis of this st udy is that this combination is 
an effective therapy alternative for oral isotretinoin. 
5.0 STUDY DESIGN 
This is a Phase 4, 12-week, single-arm, open-labe l, multi-center investiga tional study in subjects 
with severe inflammatory acne.  
This study will enroll male and female subjects, 12 years of age or older, presenting with severe 
inflammatory facial acne vulgaris with up to 2 nodules on the face and a score of 4 (severe) on 
the IGA scale, and who are, in the opi[INVESTIGATOR_689], candidates fo r oral isotretinoin. If, 
at screening, the inclusion/excl usion criteria regarding the I GA score and nodule counts are not 
met, the subject should be screen-failed a nd will not complete a baseline evaluation. Re-
screening will not be al lowed during the trial. 
Up to 25 independent study centers will particip ate in the study, and approximately 180 subjects 
will be enrolled. Subjects who meet the inclusi on criteria and none of th e exclusion criteria at 
the Screening visit will return to the clinic on Week 0 for baseline measures and to start 
treatment, which will continue for a period of up to 12 weeks. Those screened subjects who do 
not need to undergo a wash-out period ( Table 1 ; Section 6.2.2 ) may combine the Screening and 
Baseline visits, and thus attend 4 clinic visits. Sc reened subjects requirin g a wash-out period (up 
to 4 weeks) prior to baseline measurements and beginning treatment will attend a total of 
5 clinic visits. Following the Baseline (Week 0) visit, all subjects will re port to the clinic for 
efficacy and safety evaluations at Week 4, Week 8, and Week 12.  Lesion Counts and Investigator Global Assessm ents (IGAs) for a given subject are to be 
performed by [CONTACT_878967], from Week 0 through Week 12/Early 
Termination (ET) visits. A urine pregnancy test (UPT) will be required at  the Screening, Baseline, Week 4, Week 8, and 
Week 12/ET visits for all females of childbearing potential. The decision may be made by [CONTACT_878968]. 
Subjects will be provided with Cetaphil Gent le Skin Cleanser and Cetaphil Daily Facial 
Moisturizer Sun Protection Factor SPF [ADDRESS_1228023] experiences 
persistent dryness or irritation, the Investigator may consider a reduced application frequency 
for the investigational study drug ge l, as required for the sympto matic relief of skin dryness or 
irritation.  A summary of the Study Sc hedule is provided in Table 1 .  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228024] sc reening (i.e., Informed Consent 
Form [ICF] signature [CONTACT_3265] [CONTACT_49383]) to last subject out (i.e., completion of the last clinical 
trial visit by [CONTACT_405156]) is  anticipated to be approximately [ADDRESS_1228025] is expected to be from 12 to 16 weeks (12-week treatment, plus a wash-out period 
of up to 4 weeks for some subjects).  
Galderma Laboratories, LP (Galderma) may deci de to prematurely terminate or suspend the 
participation of a particular cl inical trial center (e .g., for non-inclusion or non-compliance with 
clinical trial protocol, regulati ons, or Good Clinical Practice [GCP]), or to prematurely suspend 
the clinical trial (e.g., for safety, study drug qualit y, regulatory, efficacy, or logistical reasons) at 
any time with appropriate notification. 
6.0 SELECTION AND DISPOSITION OF SUBJECTS 
6.1 Number of Subjects 
It is estimated that the screen  failure rate will be  20%; therefore, approximately [ADDRESS_1228026] fulfill all of the following criteria. 
Some criteria are to be checked at the Screening visit and/or at th e Baseline visit, as specified.  
Male and female subjects of any race, [ADDRESS_1228027] meet all of the following criteria to be eligible for inclusion in 
the study: 
1. Male or female subjects, 12 years of  age or older at Screening visit. 
2. Subjects with a clinical diagnosis of severe inflammatory acne (IGA score of 4) who, in 
the opi[INVESTIGATOR_689], are candidate s for oral isotretinoin at Screening and 
Baseline. 
3. Subjects with ≤ 2 nodules on the face, < 1 cm in diameter. 
4. Subjects willing to be photographed at study visits. Photographs may be used for 
research, marketing, promotional, and/or scientific purposes. 
5. Female subjects of child-bearing potential able and willing to use a highly effective 
method of contraception associat ed with a barrier form of  contraception from one month 
before beginning treatment to one month after treatment discontinuation.  
 
A highly effective method of contraception is defined as: bilateral tubal ligation; 
combined oral contraceptives (estrogens and progesterone) or implanted or injectable 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228028] 1 month prior to baseline; hormonal 
intra-uterine device (IUD) inserted at leas t 1 month prior to baseline; vasectomized 
partner for at least [ADDRESS_1228029]. 
Barrier forms of contracepti on include diaphragms, latex condoms, and cervical caps; 
each must be used with a spermicide. 
*For minors not yet sexually active, abstinen ce is an acceptable form of birth control. 
6. Subjects able to follow instructions a nd likely to complete all required visits. 
7. Subjects [ADDRESS_1228030] one parent or guardian read and sign the Informed Consent 
Form prior to any study-related procedure. (The parent or guardian is not required to attend the following visits unless requested.)  
6.2.[ADDRESS_1228031] be excluded from the 
study: 
1. Subjects with nodulocystic or conglobate acne, acne fulminans, or secondary acne 
(chloracne, drug-induced acne, etc.). 
2. Subjects with ≥ [ADDRESS_1228032] received topi[INVESTIGATOR_878933]: 
a. Hydroquinones, peels, phot odynamic therapy, laser therapy, microdermabrasion, 
deep chemical peel, or plastic surger y within 4 weeks pr ior to baseline. 
b. Corticosteroids, antibiotics, antibacteria ls, antiseptics, re tinoids, azelaic acid, 
dapsone, other anti-inflamm atory drugs, other acne trea tments, or light therapy 
within 2 weeks prior to baseline. 
c. Zinc-containing products, or  cosmetic procedures (fac ials, comedone extractions, 
etc.) within [ADDRESS_1228033] received systemic trea tment by [CONTACT_13216], antibiotics, or 
spi[INVESTIGATOR_878934] 4 w eeks prior to baseline. 
Note: Oral vitamin A up to the recommended daily dose (4000 - 5000 IU) is acceptable.  
8. Subjects who have started taking medications to treat a concurrent  medical condition for 
which the type and dose has not been stable in  the opi[INVESTIGATOR_878939] 
90 days prior to signing the Informed Consent Form and/or is expected to change during 
the course of the study. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 22 of 102 
 9. Subjects with a condition or circumstance wh ich, in the Investigator’s opi[INVESTIGATOR_1649], may put 
the subject at risk (e.g., a hist ory of significant renal diseas e with impairment of renal 
function), confound the study results, or interfer e with the subject’s participation in the 
study. 
10. Subjects who are at risk in terms of precauti ons, warnings, and contraindications for the 
investigational study drugs (see Appendix 14.1 for package inserts for adapalene 0.3% / 
benzoyl peroxide 2.5% gel and doxycycline hyclate tablets). 
11. Subjects with known allergy to any of the components of the study products and/or a 
known hypersensitivity to adapalen e, benzoyl peroxide, or te tracycline class antibiotics. 
12. Subjects with a skin condition which, in the Investigator’s opi[INVESTIGATOR_1649], may interfere with 
study assessments. 
13. Subjects who will be exposed to intensive ul traviolet (UV) radiation during the study 
(mountain sports, sunbathi ng, tanning beds, etc.). 
14. Subjects who have participated in an interv entional investigationa l study within [ADDRESS_1228034] be reported.  
Concomitant therapi[INVESTIGATOR_656192]: 
 Any existing therapi[INVESTIGATOR_441437]. 
 Any changes to existing therap ies (such as changes in dose or formulation) during the 
course of the clinical trial. 
 Any new therapi[INVESTIGATOR_878940]. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 23 of 102 
 6.3.2 Categories 
Previous and concomitant therapi[INVESTIGATOR_878941]: 
 Drugs/therapi[INVESTIGATOR_44793], but not limited to: prescription, OTC, birth control 
pi[INVESTIGATOR_3353]/patches/hormonal devices, vitamins, moisturizers, sunscreens, herbal medicines and 
supplements, and homeopathic preparations. 
 Medical and surgical procedures including, but  not limited to: laser/radiation procedures, 
dermal fillers, X-rays.  
Previous and concomitant therapi[INVESTIGATOR_878942]/therapi[INVESTIGATOR_13265]/or on 
the form for medical/surgical procedures in the electronic case report form (eCRF). 
Concomitant therapi[INVESTIGATOR_878943], reviewed, and updated at each visit. 
Any new concomitant therapy or modification of  an existing therapy may be linked to an 
Adverse Event (AE). A corresponding AE Form must  be completed to account for the change in 
therapy, except in some cases such as ther apy used for prophylaxis, dose modification for a 
chronic condition, etc. 
6.3.3 Authorized Concomitant Therapi[INVESTIGATOR_878944] C riteria ( Section 6.2.2 ) or in Prohibited Concomitant 
Therapi[INVESTIGATOR_014] (Section 6.3.4 ), all therapi[INVESTIGATOR_162870]. 
Subjects will be instructed to use Cetaphil Ge ntle Skin Cleanser twice daily and to apply 
Cetaphil Daily Facial Moisturizer SPF15 at least once daily; liberal application of moisturizer 
should be encouraged. Moisturizers should not be applied within 2 hours (before or after) of the 
application of study drug. The use of a moisturi zer will be documented as a Concomitant 
Therapy. Use of moisturizer will not constitute an AE. Cleanser should not be used for at least 
4 hours after study drug application. 
Higher SPF sunscreens (> SPF15) are permitte d when discussed with/approved by [CONTACT_3786], if the subject needs add itional sunscreen for outdoor activities. 
6.3.4 Prohibited Concomitant Therapi[INVESTIGATOR_878945], cleanser, moisturizer, and sunscreen 
will be permitted on the face. The following therap ies are prohibited because they may interfere 
with the efficacy and/or safety (e.g., inter action with the study medication metabolism) 
assessment of the study medication. Specific interf ering therapi[INVESTIGATOR_878946] (Section 6.2.2 ) and the following: 
 Alpha hydroxyl acid products 
 Medicated shaving creams 
 Antibacterial soaps 
 Astringents 
 Preparations with alcohol 
 Drugs that are prescribed off-label for the treatment of acne vulgaris 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228035] to continue in the trial. 
6.3.5 Procedures/Reasons for Subject  Discontinuation/Withdrawal 
Although the importance of completing the entire clinical trial shoul d be explained to the subject 
by [CONTACT_327035], any subject is free to discontinue participation in this clinical trial 
at any time and for whatever reason, specified  or unspecified, and w ithout prejudice. No 
constraints are to be imposed on the subject, and when appropriate, a subject may be treated 
with other conventional therapy when clinically indicated. Any subject who does not complete 
the clinical trial will be fully assessed, if such assessment is possible. The procedures designated for the Week 12/ET visit should be completed for al l subjects discontinuing the clinical trial and 
the appropriate eCRF page should be completed when possible. 
All discontinuations and the reasons for discontinuation ar e to be documented by [CONTACT_878969],  and also on the Adverse Event Form for 
discontinuation due to an AE. For discontinuation due to an AE, the Investig ator should ensure that the subject receives 
suitable therapy for the AE. An Investigator may decide to discontinue a subj ect from the clinical trial for safety reasons. 
Galderma may also decide to prematurely termin ate or suspend a subject’ s participation in the 
clinical trial. Potential reasons for discontinuation, as listed on the Exit Form, are defined in 
Table 2 . 
Subjects who are discontinued or w ithdrawn will not be replaced.  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228036] from the clinical trial, following the procedure described in Section [IP_ADDRESS].3. 
Lack of Efficacy Withdraw the subject from the clinical trial. This reason for discontinuation can be cited only by [CONTACT_3433] e Investigator, and is based on his 
judgment and therapeutic/disease state expectations. If only the subject 
feels there is “lack of efficacy”, mark “Subject Request” as the reason 
and document in the comment s ection of the eCRF Exit Form. 
Adverse Event Complete an AE Form. 
Subject Requesta Explain reason for withdrawal in the comment section of the eCRF 
Exit Form. (Reasons can include consent withdrawal, subject 
relocation, schedule conflicts, subject wants isotretinoin.) 
Protocol Violation Explain violation in the comment sec tion of the eCRF Exit Form. (Major 
protocol violations, especially when subject safety is concerned, will lea d
to discontinuation.) 
Lost to Follow-up Explain situation in the comment section of the eCRF Exit Form. (“Lost to Follow-up” must be confirmed with two documented phone calls and a certified letter [delivery receipt requested] without answer.) 
Othera Explain reason for discontinuation in the comment section of the 
eCRF Exit Form. (This category is to be used for a subject who 
discontinues due to a reason othe r than those specified in the 
predefined categories above.) 
a If reason for discontinuation is “subject request” or “other”, the subject will be questioned to rule out the 
possibility of an AE. (This should be documented in the comment section of the eCRF Exit Form.)  
 
7.0 CLINICAL SUPPLIES AND TR EATMENT DESCRIPTION 
7.1 Description and Use of Study Medications 
Descriptions and use of the study medications, both the investigati onal drugs and the non-
investigational products , are summarized in Table 3 . Additional information is available in the 
package inserts for the investigational study drugs ( Appendix 14.1).  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 27 of 102 
  
7.1.2 Method of Treatment Assi gnment and Blinding 
Not Applicable. This is an open-label study. All subjects will receiv e the same treatment. 
7.1.3 Study Medication Kit Number 
Not Applicable. No kits will be used. 
7.1.4 Instructions for Use and Administration  of Adapalene 0.3% / Benzoyl Peroxide 
2.5% Gel 
Each subject will receive the investigational study drug adapalene 0.3% / benzoyl peroxide 
2.5% gel in 45 g pump bottles duri ng the course of the study ( Table 3 ).   
This study drug should be applied to dry skin once daily for 12 weeks, at night after washing with Cetaphil Gentle Skin Cl eanser (provided by [CONTACT_1034]; Table 3 ). A pea-sized amount of 
adapalene 0.3% / benzoyl peroxide 2.5% gel should be put on th e fingertip and applied to the 
forehead. The procedure is repeated with a pea- sized amount applied to each cheek and to the 
chin and nose, being careful to avoid applicati on to the nostrils, mouth, lips, and eyelids. The 
objective is to cover the entire f ace with a thin film of  the treatment, even if there are areas on 
the face that do not have acne. While there are five areas of the face to be treated (forehead, right cheek, left cheek, chin, a nd nose), four pea-sized amounts of the study drug are typi[INVESTIGATOR_878947]. Designated study personnel should demonstrate how 
to apply the study drug by [CONTACT_2329] a moisturizer as a tool, to show the s ubject the amount of study 
drug to use daily and the method of applicati on. The product should not be applied to cuts, 
abrasions, or eczematous or sunburned skin. 
Signs and symptoms of local tolerability are possible during treatment (erythema, scaling, 
dryness, and stinging/burning). To prevent dry skin, subjects will be requested to use a 
moisturizer (Cetaphil Daily Facial Moisturizer SPF15, provided by [CONTACT_1034]) throughout the 
study as needed. If a subject experiences persiste nt dryness or irritation,  the Investigator may 
consider a reduced application frequency of the investigational study drug gel as required for 
the symptomatic relief of skin dryness or irritation ( Section 7.1.6). 
Subjects should be instructed to store the adap alene 0.3% / benzoyl peroxide 2.5% gel at room 
temperature in a closed container, away from  light, heat, and moistu re. The study drug should 
not be refrigerated or frozen. 
7.1.5 Instructions for Use and Admini stration of Doxycycline Hyclate 
At the Baseline/Week [ADDRESS_1228037] will receive two 120-count bottles of the 
investigational study drug doxycycline hyclate (50 mg tablets) and will be resupplied at each 
study visit (Week 4 and 8 onl y) with one new bottle ( Table 3 ). During the Baseline/Week [ADDRESS_1228038] 100-mg dose of doxycycline hyclate at the same 
time as the adapalene 0.3% / benzoyl peroxide 2.5 % gel treatment that evening (i.e., receiving 
only a 100-mg dose on Day 0). They will take the second 100-mg dose the next morning, beginning the [ADDRESS_1228039] will be instructed to completely use one bottle of doxycycline hycl ate before starting a subsequent bottle. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228040] will take two 50-mg tablets of doxycycline 
hyclate in the morning and at night, for a tota l of four tablets (a to tal of 200 mg) daily for 
[ADDRESS_1228041] experiences persiste nt dryness or irritation despi[INVESTIGATOR_878948] e of the moisturizers provided 
(Section 7.1.4), the Investigator may consider dose m odification; i.e., reducing the once-daily 
treatment regimen to every other day. The Investigator should atte mpt to return the subject to 
once-daily treatment within two weeks.  
If this dose modification occurs between Baseli ne Week 0 and Week 4, and lasts more than 2 
weeks after the onset date of the dryness or irritation, the signs or symptoms of local tolerability 
should be recorded as an AE. After the Week 4 vi sit, the signs or symptoms related to this dose 
modification should be recorded as an AE, rega rdless of the duration of  the dose modification. 
7.1.7 Other Supplies 
Galderma will supply the UPTs, Cetaphil® Daily Facial Moisturizer  SPF15 or equivalent ( Table 
3), and Cetaphil® Gentle Skin Cleanser or equivalent ( Table 3 ). 
7.2 Investigational Study Drug Packaging and Labeling 
Adapalene 0.3% / benzoyl peroxide 2.5% gel is packaged in a 45 g bottle with a pump. A 
representation of the packag e insert is provided in Appendix 14.1. 
Doxycycline Hyclate 50 mg tablets are packag ed in bottles of 120 tablets per bottle. A 
representation of the packag e insert is provided in Appendix 14.1. 
7.3 Supplies Management 
7.3.1 Study Medication Accountability 
The Investigator or designee will maintain accurate records of the following: 
 Reconciliation of all stu dy medications (investiga tional study drugs and non-
investigational study products; Table 3 ) delivered to/received at the clinical trial center 
 Overall inventory for study medicati ons at the clinical trial center 
 Study medications dispensed to each subject 
 Study medications returned by [CONTACT_233963] s ubject to clinical trial center 
 Used and unused investigational study drug returned to the Spons or (or alternative 
disposal) 
Upon receipt of the study medication, the clinical trial center pe rsonnel responsible for managing 
the supplies must conduct a complete inventory of all study medication and submit a signed copy 
of the Transfer of Clinical Supply Record  (a.k.a. packing slip) received  with the materials to The 
Coghlan Group via fax ([PHONE_18200] or email [EMAIL_16726] .  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 29 of 102 
 None of the used or unused Cetaphil® moistu rizers, Cetaphil® cleansers, or UPTs will be 
returned to the Sponsor.  
All clinical investigational study drug (ada palene 0.3% / benzoyl peroxide 2.5% gel and 
doxycycline hyclate tablets) sent to the Investig ator/Institution will be accounted for, and no 
unauthorized use is permitted. 
7.3.[ADDRESS_1228042] be stored in a safe and secure area with restricted access, under the 
storage conditions specified by [CONTACT_83805] ( Table 3 ; Sections 7.1.4  and 7.1.5). 
7.3.3 Study Medication Dispensing and Return 
Only qualified study personnel (as designated by [CONTACT_079]) will be responsible 
for dispensing study medication. Upon dispensing, the designated study personnel will 
document on the medication bottles the date of di spensing, the SIN of the subject receiving the 
study medication, and the initials  of the person responsible for dispensing the medication.  
Full accountability, including the date of return and initials of the study personnel responsible 
for receipt, will be performed and documented for all study medications retu rned to the clinical 
study center as required. 
Subjects will be instructed by [CONTACT_878970] l, and about the importance of retu rning their 
investigational study drugs (used and/or unused) at each visit. Each subject will receive 
Cetaphil Gentle Skin Cleanser, Cetaphil Da ily Facial Moisturizer SPF15, 45 g pumps of 
adapalene 0.3% / benzoyl peroxide  2.5% gel (to be weighed prio r to dispensing and upon return) 
and 120-count bottles of 50 mg doxycycline hycla te (to be counted upon return) during the 
course of the study.  The adapalene 0.3% / benzoyl peroxide 2.5% ge l and doxycycline hyclate will each be labeled 
with the protocol number and a four-digit bott le number. Study personnel should appropriately 
document the dispensation and return of study me dication on the site’s drug accountability log. 
At the appropriate visits, subjects will retu rn their investigational study drug and will be 
dispensed new study drug; the proc ess will be repeated throughout the subject’s participation.  
In the event of early termination/suspension of the clinical trial, a rapid recall of 
investigational study drug will be initiated. The Investigator or designee must immediately 
instruct the subjects to stop the study medication regimen and return the investigational study 
drug to the clinical trial center. 
For subjects who do not complete the entire clini cal trial, all used and unused investigational 
study drug should be returned by [CONTACT_878971]. The Investigator will return the investigational study drug to The Coghlan Group at the end 
of the study when all subjects have exited the study. Coghlan will then reconcile the 
investigational study drug by c ounting the returned pumps and counting the number of 
tablets to create a report of all study drug accountability (pump and tablet counts); the report will be provided to the Sponsor. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 30 of 102 
 7.4 Treatment Compliance Management and Records 
Investigational study drug will be collected from subjects at Weeks 4, 8, and 12/ET visits. To 
assess subject compliance, the Study Personne l will weigh the adapalene 0.3% / benzoyl 
peroxide 2.5% gel bottle before dispensing a nd upon subject returning the study drug at each 
visit. The doxycycline hyclate tablets will be counted upon subject returning the study drug at 
each visit. (A count of the pumps of adapalene 0.3% / benzoyl peroxide 2.5% gel and 
doxycycline hyclate tablets will be confirmed by [CONTACT_878972] [ Section 7.3.3 ].) Other than 
documentation of dispensing to the subjects, no a dditional accountability w ill be required for the 
non-investigational products  (i.e., Cetaphil cleanser, Cetaphil moisturizer).  
Subjects will be questioned regarding the inves tigational study drug gel application technique 
and use of any additional topi[INVESTIGATOR_878949] (including OTC products, and 
sunscreen usage for outdoor activities) which will be recorded in the Concomitant Medication 
Form. Subjects will also be questioned about the number of missed gel applications (if any) 
between study visits. 
8.[ADDRESS_1228043] ( Section 8.2 ). The initials of the Investigator performing the assessment will 
be captured on the eCRF. In the event there is a change in the assigned In vestigator for a given 
subject, the reason for change must be documen ted. Untrained evaluators  are not allowed to 
perform these assessments. If it is not possible to use the same evaluator to follow a given 
subject, the Sponsor recommends  that evaluations by [CONTACT_878973] (both Investigators should examine the subj ect together and discu ss findings) for at least 
one visit. This should be documented in the appropriate Comments  section of the eCRF. 
8.2 Efficacy Measurements 
Efficacy assessments performed by [CONTACT_878974] 4, 8, and 12 include 
IGA, Inflammatory Lesion Counts (papules an d pustules), Non-inflammatory Lesion Counts 
(open and closed comedones), and Oral Isotretinoin Evaluation. Only the subject’s face will be evaluated for IGA and Lesion Counts. The Subjec t’s Assessment of Acne Improvement is an 
efficacy-related subject survey. 
The same Investigator will evaluate a given subj ect at every visit throughout the study. The same 
Investigator will evaluate whether, in his opi[INVESTIGATOR_3078] n, the subject is suitable for an oral isotretinoin 
prescription at every study visit. The IGA assessment should be perf ormed before the lesion counting. 
8.2.1 Investigator’s Global Assessment (IGA) 
A Board Certified Dermatologist will assess the subject’s acne se verity using the IGA scale at 
every visit, performing a static  (“snap-shot”) evaluation of acn e severity. No reference to 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228044]’s facial acne. 
The IGA is dichotomized, such th at Success is clearly defined as  0=Clear and 1=Almost Clear. 
The IGA Severity Scale is presented in Table 4 . 
Table 4. Investigator’s Global  Assessment Severity Scale 
Severity Scale Description 
[ADDRESS_1228045] Clear A few scattered comedones and a few small papules. 
2 Mild Easily recognizable; less than half the face is involved. Some 
comedones and some papules and pustules. 
[ADDRESS_1228046]-baseline visit. 
Each type of lesion will be c ounted separately and recorded on  the appropriate eCRF page. The 
lesion counts will be taken from the forehead, right cheek, left cheek, chin, and nose ( see 
Appendix 0).  
The following lesion types will be counted: 
 Inflammatory Lesions 
o Papule – a small, red, solid elevation equa l to or less than 0.5 cm in diameter. 
o Pustule – a small, circumscribed elevation of the skin that contains yellow-white 
exudate. 
 Non-inflammatory Lesions 
o Open Comedone – a pi[INVESTIGATOR_249587] (blackhead). 
o Closed Comedone – a tiny white papule (whitehead). 
Nodules/Cysts, defined as circumscribed, elevated, solid lesions generally more than 1 cm in diameter with palpable depth, are co unted at Screening/Baseline visit only. 
No more than 2 
nodules/cysts will be allowed for study participation (Exclusion Criterion #2, Section 6.2.2). 
Nodules/Cysts are not counted at post-Baseline visits.  
8.2.3 Oral Isotretinoin Evaluation 
At each study visit, subjects will  be evaluated to determine if, in the opi[INVESTIGATOR_689], 
they are still candidates for oral isotretinoin. Regardless of the resu lts, subjects will not be exited 
from the study due to this evaluation, a nd will continue participation in the study. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228047] s at Baseline and at every subsequent visit. 
8.4 Safety Measurements 
Safety measurements include Local Tolerab ility Assessment and th e Incidence of AEs. 
8.4.1 Local Tolerability Assessment 
Signs and symptoms of local tole rability (erythema, scaling, dr yness, and/or stinging/burning) 
will be evaluated by [CONTACT_878975]-baseline visit. 
The Investigator will record stinging/burning af ter discussion with the subject, based on the 
prior day’s application. The Investigator will  ask an open-ended question such as, “Have you 
experienced any sensations immediately following  dosing)?” taking care not to influence the 
subject’s answer. 
Erythema, scaling, dryness, and stinging/burning will be graded ( Table 5 ) at Baseline and each 
post-Baseline visit (face only).  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 33 of 102 
  
Table 5. Local Tolerability Severity Scale 
Severity Description 
Erythema – abnormal redness of the skin  
0 None No erythema 
1 Mild Slight pi[INVESTIGATOR_264661]  
2 Moderate Definite redness, easily recognized  
3 Severe Intense redness 
Scaling – abnormal shedding of the stratum corneum 
0 None No scaling 
1 Mild Barely perceptible shedding, noticeable only on light scratching or 
rubbing 
2 Moderate Obvious but not profuse shedding  
3 Severe Heavy scale production  
Dryness – brittle and/or tight sensation  
0 None No dryness  
1 Mild Slight but definite roughness  
2 Moderate Moderate roughness  
3 Severe Marked roughness  
Stinging/Burning – prickling pain sensation immediately after (within 5 minutes) dosing  
0 None No stinging/burning  
1 Mild Slight warm, tingling/stinging sensation; not really bothersome  
2 Moderate Definite warm, tingling/stinging  sensation that is somewhat bothersome  
3 Severe Hot, tingling/stinging sensation that has caused definite discomfort  
Note: Stinging/Burning at the Baseline visit is to be assessed as none (0). 
An AE will be recorded if the severity of the signs and symptoms is such that: 
 The subject’s participation in the study is interrupted at the subject’s request or at 
the Investigator’s request. 
 The subject permanently discontinues the trea tment at the subject’s request or at the 
Investigator’s request. 
 The subject requires concomitant prescription or OTC therapy (other than moisturizers). 
Note: Need for increased moisturizer use does NOT constitute an AE. 
Any new sign or symptom not included in the sc heduled evaluation of tolerability should be 
recorded as an AE, including those of mild intensity. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 34 of 102 
 8.4.2 Adverse Events  
Throughout the course of the study, all AEs wi ll be monitored and reported on the eCRF 
Adverse Event Form, disclosing any requested and known information. When AEs occur, the 
main concern is the safety of the study subjects. 
[IP_ADDRESS] Definitions 
The following definitions of terms are guided by [CONTACT_5787] 
(ICH) and the U.S. Code of Fe deral Regulations (21 CFR 312.32). 
[IP_ADDRESS].1 Adverse Event  
An AE can be any unfavorable and/or unintended sign (including an abnormal laboratory 
finding), symptom, or disease tem porally associated with the use of a medicinal/investigational 
product, whether or not related to the medicinal/investigatio nal products or to the study 
procedures. 
Thus any new sign, symptom or disease, or clinically significant increase in  the intensity of an 
existing sign, symptom or disease, should be cons idered as an AE. All ev ents that occur after 
signing of the subject ICF until the subj ect is off-study should be recorded.  
Notes: 
- Clinically significant worsening of the dis ease/condition being evaluated, which occurs 
during the study, is considered an AE. 
- Any new signs or symptoms suffered by [CONTACT_878976] s hould also be reported as an AE. 
Pregnancy is not to be consider ed an AE, but must be reported promptly and followed up as 
described in Section [IP_ADDRESS].3. 
Any AE, whether or not it is related to the investigational st udy products or to the study 
procedures, will be reported on the eCRF Adverse Event Form along with the diagnosis 
(preferably) or description of th e signs/symptoms, the date of ons et, the severity, the seriousness, 
the relationship and the action take n with the investigational product,  the treatment given to treat 
the AE, and the final AE outcome.  
Assessment of AE seriousness, severity, and causali ty will be based on specific definitions (see, 
respectively, Sections [IP_ADDRESS].2, [IP_ADDRESS].5, and [IP_ADDRESS].6). 
Side effects may be expected dur ing treatment with Adapalene-BP O Gel, the characteristics of 
which are described in this pr otocol (e.g., erythema, scaling, dr yness, and stinging/burning). The 
course of these expected events will be assessed and reported on th e tolerability assessments. An 
Adverse Event Form will be completed only if the severity of the expected signs and symptoms 
is such that an interruption of the Subject’s participation in th e study occurred at Investigator’s 
decision and/or if a concomitant medication (exc ept moisturizer) is prescribed to treat the 
sign/symptom. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 35 of 102 
 [IP_ADDRESS].2 Serious Adverse Event 
A serious adverse event (SAE) is any untow ard medical occurrence that at any dose: 
 Results in death 
 Is life-threatening 
 Requires inpatient hospi[INVESTIGATOR_281216] 
 Results in persistent or significant disability/incapacity 
 Is a congenital anomaly/birth defect 
Important medical events  that may not result in death, be life-threaten ing, or require 
hospi[INVESTIGATOR_878950], based upon appropriate medical judgment, 
they may jeopardize the safety of the subject, an d may require medical or surgical intervention to 
prevent one of the outco mes listed in this definition. Exampl es of such events are intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasia, or 
convulsions that do not re sult in hosp italization. 
Note: The term “life-threatening” refers to an ev ent in which the subject was at risk of death at 
the time of the event; it does not refer to an ev ent that hypothetically might have caused death if 
it was more severe. 
Inpatient hospi[INVESTIGATOR_878951] a night 
at the hospi[INVESTIGATOR_307]. The criterion for prolongation of hospi[INVESTIGATOR_878952]. Hospi[INVESTIGATOR_878953] a diagnostic  tests (even if related to an AE), elective 
hospi[INVESTIGATOR_878954], admission to a day- care facility, social admission (e .g., if the subject has no place to 
sleep), or administrative admission (e.g., for a yearly examination). 
[IP_ADDRESS].3 Unexpected Adverse Drug Reaction 
According to ICH E6, an unexpected adverse drug reaction is defined as an adverse reaction, the 
nature or severity of which is not consistent  with the applicable study medication information 
(e.g., Investigator’s Brochure for an unappr oved investigational drug or the package 
insert/summary of product character istics for an approved product). 
[IP_ADDRESS].[ADDRESS_1228048] (or the subject’s surroga te) signs the ICF to the end of  the subject’s participation. 
The Sponsor should be informed if the Investigator becomes aware of any unusual safety 
information or any safety information that appear s to be drug-related involving a subject who has 
participated in a clinical tria l, even after a subject has completed the clinical trial. The 
Investigator should be diligent in looking for possi ble latent safety effects that may appear after 
the medication has been discontinued. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 36 of 102 
 [IP_ADDRESS].[ADDRESS_1228049] appropriate according his medical 
judgment.  
Mild: Awareness of signs or symptom, but easily tolerated (acceptable) Moderate:  Discomfort, enough to cause interferen ce with usual activ ity (disturbing) 
Severe:  Incapacitating, with inability to work  or perform usual activity (unacceptable) 
[IP_ADDRESS].6 Relationship to the study treatment 
The Investigator is to determine whether there is a reasonable causal relationship between the 
study treatment and the AE. Medical judgment s hould be used to determine the relationship, 
considering all relevant factors, including the pattern of reaction, temporal relationships, relevant 
medical history, and confounding factors such as  co-medication or concurrent diseases. 
The expression “reasonable causal re lationship” is meant to convey in general that there are facts 
or arguments to suggest a causal rela tionship (ICH E2A, Section IIIA 1). 
The relationship assessment for an AE is to be  completed using the fo llowing definitions as a 
guideline for all AEs occurring during clinical  trials conducted or sponsored by [CONTACT_83805]: 
 
Reasonable possibility:  
According to the reporting Investigator, there is a reasonable possibility (i.e., suggestive 
evidence or arguments) that there is a causal re lationship irrespective of the dose administered 
between the study treatment (invest igational produc t) and the AE. 
No reasonable possibility:  
No suggestive evidence or arguments can be id entified regarding a causal relationship between 
the study treatment or the clinical tr ial protocol procedure and the AE. 
[IP_ADDRESS] Reporting Procedures 
[IP_ADDRESS].[ADDRESS_1228050] (or the subject’s surrogate) signs 
the ICF to his final visit. Any AE occurring during the AE reporting period, whether it is related 
to the study treatment or not, will be recorded  immediately in the source document, and 
described on the Adverse Event Form of the eCRF along with the date of onset, severity, 
relationship to the study treatment, and outco me, without omitting any requested and known 
information. Additional information may be reque sted under certain circumstances. AEs assessed 
as related to the treatment will be monitored until they are completely or satisfactorily resolved. 
Other AEs will be monitored until the last visit if they are not resolved or satisfactorily resolved. 
The Investigator will obtain and ma intain in the subject’s files all pertinent medical records, 
information and medical judgment from colleague s who assisted in the treatment and follow-up 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228051]’s personal physician or 
hospi[INVESTIGATOR_99391]. 
For SAEs (see Section [IP_ADDRESS].2), and pregnancies (see Section [IP_ADDRESS].3 ), the event must be 
reported by [CONTACT_154501] e-mail within 24 hours (contact [CONTACT_77268] 
[IP_ADDRESS].2).  
If the Subject discontinues due to an AE, the AE and Exit Forms must be completed. 
[IP_ADDRESS].[ADDRESS_1228052] do the following: 
1. Take prompt and appropriate medical action, if necessary. The safety of the subject is the 
first priority. Additional contact [CONTACT_414230]’s site file. 
2. Complete the Adverse Event Form provide d in the eCRF as fully as possible. 
3. Ensure that the event is classified as an SAE. 
4. Complete the Serious Adverse Event Form (available in the Study Reference Manual). 
Send the completed form within 24 hours to Ad vanced Clinical (AC) Pharmacovigilance 
(PV) by [CONTACT_6791] ([PHONE_18201]), or scan the co mpleted form and send within 24 hours by e-
mail ( [EMAIL_16727] ). Include any other relevant information or 
medical records (e.g., physical  examination findings).  
AC PV will inform Galderma of th e SAE by [CONTACT_6791] ([PHONE_18202]) and by e-mail 
([EMAIL_16728] ) within [ADDRESS_1228053], identifiable reporter, study treatment, 
description of the event (dia gnosis). The demographics, me dical history, previous and 
concomitant therapi[INVESTIGATOR_014], and AE pages of the eCRF must be completed and available for 
review in the Electronic Data Capture (EDC) system at  the time of the report. 
5. Monitor and record the progress of the event until  it resolves or reaches a clinically stable 
outcome, with or without sequelae. For all a dditional follow-up evaluations, complete or 
update a Serious Adverse Event Form, and then  fax or scan; send by e-mail all additional 
follow-up information to the AC PV within 24 hours. SAEs will be monitored until the 
Investigator and Sponsor agree that the event is satisfactorily resolved. 
Report SAEs to: 
Advanced Clinical Pharmacovigilance 
SAE eFax:  [PHONE_18201] SAE Hotline:  [PHONE_18203] Email: [EMAIL_16727] 
6. Inform AC PV of the final outcome of th e event. Send a revised or updated Serious 
Adverse Event Form and Adverse Event Form, if appropriate. 
7. Comply with the applicable regulatory requirement(s) related to the reporting of SAEs to 
the regulatory authority(ies), Instituti onal Review Board (IRB)/Independent Ethics 
Committee (IEC) and other pharmaceutic al companies (as appropriate). 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 38 of 102 
 [IP_ADDRESS].[ADDRESS_1228054] be re ported in the same manner as an SAE (within 
24 hours, as described in Section [IP_ADDRESS].2) and monitored until its final outcome in order to 
ensure the complete collection of safety data for Galderma products. 
The Sponsor’s Pharmacovigilance Department has instituted a Pregnancy Exposure Follow-up 
program that allows for the follow-up of all e xposures in pregnant women. Pregnancy exposure 
is defined as an exposure to the investigati onal study drug during the subject’s pregnancy.   
If a subject becomes pregnant, the In vestigator is to do the following: 
1. Withdraw the subject from the clinical trial  
2. Complete appropriate final vis it evaluations and eCRF pages. 
Upon the report of a pregnanc y occurring during the study, the Sponsor’s Pharmacovigilance 
Department will contact [CONTACT_878977]-up Program. 
If the pregnancy leads to an abortion (voluntary, spontaneous, or therapeutic), ectopic pregnancy, 
in-utero death, or congenital anomaly, the Invest igator will follow the procedure for declaration 
of an SAE (see Section [IP_ADDRESS].2).  
CCI
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
Final Date: 28 Jun 2016   Page 39 of 102 
 
CCI
CCI
CCI
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 40 of 102 
 8.6 Appropriateness of Measurements 
The measurem
ents to be used for assessment of efficacy in this clinical trial are recommended by 
[CONTACT_2165] (FDA) in Guidance for Industry, Acne Vulgaris: Developi[INVESTIGATOR_97209]  (2005)38, and are widely accepted clinic al endpoints in st udies evaluating 
treatments for acne vulgaris.  
Change from Baseline in Inflammatory and N on-inflammatory Lesion Counts at Week 12 is a 
commonly used practice to assess severity of acn e. All lesions will be counted, including those 
on the nose. An IGA will also be performed, using a 5-point s cale to evaluate acne severity. As recommended 
by [CONTACT_137349], IGA Success is defined as Clear (Grade 0) or Almost Cl ear (Grade 1) at a 
specified time point. Therefore, IGA Success Rate  for this study is defined as the number and 
percent of subjects rated as Clear or Almost Clea r; Success Rate will be summarized at Weeks 4, 
8, and 12. 
Collection of AEs and SAEs is a standard-of-ca re medical assessment for safety monitoring of 
patients participating in clinical trials. 
9.0 CLINICAL TR IAL VISITS 
9.1 Description of Clinical Trial Visits 
Please refer to the Schedule of Assessments ( Table 1 ). 
A written, signed ICF ( signed Assent Form for minors) which includes Photography 
Consent and HIPAA authorization must be obtai ned prior to performi ng any clinical trial-
related evaluations and/or procedures. 
9.1.[ADDRESS_1228055] and parent/leg al representative (as 
applicable). 
CCI
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 41 of 102 
 2. Obtain the appropriate approved ICF (which  contains Photography Consent and HIPAA 
authorization), and Assent form, if needed. Provide signed copi[INVESTIGATOR_878955]/legal representative (as applicable). 
3. Assign a SIN to the subject after the ICF is si gned. This number will be used to identify 
the subject throughout the study. 
4. Collect information regarding demographics, relevant medical hist ory, and previous and 
ongoing medication/therapy use. 
5. Verify Inclusion/Exclusion Criteria and eval uate the subject for entry into the study. 
6. Perform a UPT on all females of child-bearing potential.  
7. Verify that the subject is not wearing makeup. In the event the subject is wearing make-up, 
the appointment may be rescheduled, or the subject  can be instructed to wash the face with a 
Gentle Skin Cleanser; wait for [ADDRESS_1228056] is a candidate for oral isotretinoin. 
10. If no wash-out is required, Screening a nd Baseline visits can be combined.  
If Screening and Baseline visits need to occur on separate days (i.e., for subjects who have 
received, applied, or taken treatments as noted in Exclusion Criteria 6 and 7) and additional 
time for wash-out is required, schedule a return  appointment for the Ba seline visit according 
to the wash-out period for that medication (maximal 28 ± 3 days after Screening). Instruct the 
subject to arrive at the site for the visit without make-up. 
If Screening and Baseline visits will occur same day, complete the Baseline assessments. 
9.1.2 Baseline Visit 
The following procedures will be performed at the Baseline visit. 
If Screening and Baseline visits occur on separa te days, begin Baseline assessments at Step 1 
and complete all assessments listed. If Screen ing and Baseline visits occur on the same day, 
begin Baseline assessments at Step 7, after co mpletion of Screening assessments and a UPT for 
all females of child-bearing potential (Step 3 below). 
Note: The Investigator/Evaluator for a particul ar subject should remain the same for the 
duration of the study . 
1. Assess concomitant medication/th erapy/procedures and verify required wash-out period has 
been completed for any previous medications/therapi[INVESTIGATOR_014]. 
2. Re-confirm Inclusion/Exclusion Cr iteria and re-evaluate the subject for entry into the study. 
If the subject no longer meets e ligibility criteri a, no further assessments  are required. Enter 
the subject into EDC as a screen failure. 
3. Perform a UPT on all females of child-bearing potential. 
‐ Urine pregnancy testing is mandatory for all females of child-bearing potential.  
‐ For a subject with a pre-menstrual status at the previous visit, confirm that her 
childbearing potential status ha s not changed (began menses). If her status has changed, 
follow the pregnancy testing schedule for fema les of child-bearing po tential correlating 
to the visit that menses began. Confirm that  the subject agrees to use two effective 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228057] ed to wash the face 
with a Gentle Skin Cleanser; wait for 30 minutes prior to beginning the evaluations. 
5. Evaluate acne on the face only, using IGA scale (see Section 8.2.1). 
6. Determine if, in the opi[INVESTIGATOR_273554], the subject is a candidate for oral 
isotretinoin (see Section 8.2.3). 
7. Conduct the facial Lesion Counts (see Section 8.2.2). 
8. Perform the Baseline Local Tolerability Assessment (erythema, dryness, scaling, 
stinging/burning; see Section 8.4.1 ). Note: Stinging/burning at the Baseline visit is to be 
assessed as None (0). 
9. Question the subject about AEs by [CONTACT_878978]-ended question, taking care not to 
influence the subject’s answer, such as: “Hav e you had any new symptoms, injuries, illness 
or side-effects or worsening of pre-existing conditions?” Record all ev ents as appropriate 
on the corresponding AE eCRF pages (see Section 8.4.2 ). 
10. Have the subject (if 13 years of age or older at the time of In formed Consent) complete the 
Acne QoL form (see Section 8.5.5 ). Subjects [ADDRESS_1228058] 
leaving the office. 
12. Obtain photographs of facial acne (see Section 8.5.1 ).  
13. Weigh the adapalene 0.3% / benzoyl peroxide  2.5% gel and record the pre-dispensed 
weight in drug accountability reco rd and/or source documentation.  
14. Dispense study medications as listed below to the subject:  
Product Quantity 
Cetaphil Daily Gentle Cleanser 1 bottle 
Cetaphil Daily Facial Moisturizer SPF 15 1 bottle 
Adapalene 0.3% / Benzoyl Peroxi de 2.5% Gel 1 bottle with pump 
Doxycycline Hyclate  2 bottles 
Give verbal and written (Galderma Prot ocol GLI.04.SPR.US10355 Subject Instruction 
Sheet) instructions to the subject (or parent/le gal representative, as appropriate) regarding 
when and how to properly apply and take the st udy drugs. Instructions are to include the use 
of cleansers and moisturizers, sunscreens, and other concomitant treatments or medications. 
Demonstrate how to apply the study drug gel by [CONTACT_878979], to show the subject the 
amount of study drug gel to use daily  and the method of application. 
Instruct the subject to bring the investigatio nal study drugs to all study visits for review. 
(Subjects do not need to bring the cleans er and moisturizer to the study visits.) 
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228059] to use a cleanser and mois turizer, throughout the duration of the study 
(e.g., Cetaphil Gentle Skin Cleanser and Ceta phil Daily Facial Moisturizer SPF15 or 
equivalent). Liberal application of moisturizers should be encouraged.  
16. Schedule a return appointment for the Week 4 Visit (a visit window of  ± 3 days will be 
allowed), and remind the subject to bring th e investigational study drugs to the next 
scheduled visit and to arrive at the site for the visit without make-up.  
9.1.3 Week 4 Visit (± 3 days) 
The following procedures will be performed at the Week 4 visit. 
1. Perform a UPT on all females of child-bearing potential. 
‐ Urine pregnancy testing is mandatory for all females of child-bearing potential. 
‐ For a subject with a pre-menstrual status at the previous visit, confirm that her 
childbearing potential status ha s not changed (began menses). If her status has changed, 
follow the pregnancy testing schedule for fema les of child-bearing potential correlating 
to the visit that menses began. Confirm that the subject agrees to use an effective form 
of birth control while in the study, until at least one m onth after the last study drug 
application. 
2. Assess concomitant medicat ion/therapy/procedures. 
3. Verify that the subject is not wearing makeup. In the event the subject is wearing make-up, 
the appointment may be rescheduled, or the su bject should be instruct ed to wash the face 
with a Gentle Skin Cleanser; wait for 30 minutes prior to beginning the evaluations. 
4. Evaluate acne on the face only, using IGA scale (see Section 8.2.1). 
5. Conduct the facial Lesion Counts (see Section 8.2.2). 
6. Determine if, in the opi[INVESTIGATOR_125362], the subject is stil l a candidate for oral 
isotretinoin (see Section 8.2.3). 
7. Perform the Local Tolerability Assessment (erythema, dryness, scaling, 
stinging/burning; see Section 8.4.1 ). 
8. Question the subject about the occurrence of AEs and record all events as appropriate on the corresponding AE eCRF pages (see Section 8.4.2 ). 
9. Obtain photographs of facial acne (see Section 8.5.1 ). 
10. Collect returned Investigati onal Study Drugs (used and unused) and perform accountability 
evaluations as described in Section 7.4 . Discuss any concerns with compliance and note 
discussion in source documentation. 
11. Obtain a new bottle of the adapalen
e 0.3% / benzoyl peroxide 2.5% gel, weigh, and 
document the weight in drug accountability  record and/or source documentation.  
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228060] Quantity 
Cetaphil Daily Facial Moisturizer SPF 15 1 bottle 
Adapalene 0.3% / benzoyl peroxi de 2.5% gel 1 bottle with pump 
Doxycycline Hyclate - new bottle 1 bottle 
Doxycycline Hyclate – redispense bottle 
with unused medication from previous visit 1 bottle 
Provide verbal and/or written instruc tions (Galderma Protocol GLI.04.SPR.US10355 
Subject Instruction Sheet – if needed) to th e subject (or parent/legal representative, as 
appropriate) on when and how to properly apply and take the study drugs.  
13. Schedule a return appointment for the Week 8 Visit (a visit window of  ± 3 days will be 
allowed), and remind the subject to bring th e investigational study drugs to the next 
scheduled visit and to arrive at the site for the visit without make-up.  
9.1.4 Week 8 Visit (± 3 days) 
The following procedures will be performed at the Week 8 visit. 
1. Perform a UPT on all females of child-bearing potential. 
‐ Urine pregnancy testing is mandatory for all females of child-bearing potential. 
‐ For a subject with a pre-menstrual status at the previous visit, confirm that her 
childbearing potential status ha s not changed (began menses). If her status has changed, 
follow the pregnancy testing schedule for fema les of child-bearing potential correlating 
to the visit that menses began. Confirm that the subject agrees to use two effective forms 
of birth control while in the study, until at least one m onth after the last study drug 
application. 
2. Assess concomitant medicat ion/therapy/procedures. 
3. Verify that the subject is not wearing makeup. In the event the subject is wearing make-up, 
the appointment may be rescheduled, or the su bject should be instruct ed to wash the face 
with a Gentle Skin Cleanser; wait for 30 minutes prior to beginning the evaluations. 
4. Evaluate acne using IGA scale on the face (see Section 8.2.1 ) 
5. Conduct the facial Lesion Counts (see Section 8.2.2). 
6. Determine if, in the opi[INVESTIGATOR_125362], the subject is stil l a candidate for oral 
isotretinoin (see Section 8.2.3). 
7. Perform the Local Tolerability Assessment (erythema, dryness, scaling, 
stinging/burning; see Section 8.4.1 ). 
8. Question the subject about the occurrence of AEs and record all events as appropriate on the corresponding AE eCRF pages (see Section 8.4.2 ). 
9. Collect returned Investigati onal Study Drugs (used and unused) and perform accountability 
evaluations as described in Section 7.4 . Discuss any concerns with compliance and note 
discussion in source documentation. 
10. Obtain a new bottle of the adapalene 0.3% / benzoyl peroxide 2.5% gel, weigh, and 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228061] and/or source documentation.   
11. Dispense study medications as listed below to the subject:  
Product Quantity 
Cetaphil Daily Facial Moisturizer SPF 15 1 bottle 
Adapalene 0.3% / Benzoyl Peroxi de 2.5% Gel 1 bottle with pump 
Doxycycline Hyclate – new bottle 1 bottle 
Doxycycline Hyclate – redispense bottle with 
unused medication from previous visit 1 bottle 
Again give verbal and/or written instruct ions (Galderma Protocol GLI.04.SPR.US10355 
Subject Instruction Sheet) to the subject (or parent/legal representa tive, as appropriate) on 
when and how to properly apply and take the study drugs, if needed.  
12. Schedule a return appointment for the Week 12 Visit (a visit window of ± 3 days will be 
allowed), and remind the subject to bring all study medications (both investigational study 
drugs and non-investigational study products) to th e next scheduled visit and to arrive at the 
site for the visit without make-up.  
9.1.5 Week 12/Early Termination Visit (± 3 days) 
The following procedures will be performed at the Week 12/ET visit. 
1. Perform a UPT on all females of child-bearing potential. 
‐ Urine pregnancy testing is mandatory for all females of child-bearing potential. 
‐ For a subject with a pre-menstrual status at the previous visit, confirm that her 
childbearing potential status ha s not changed (began menses). If her status has changed, 
follow the pregnancy testing schedule for fema les of child-bearing potential correlating 
to the visit that menses began. Confirm that the subject agrees to use two effective forms 
of birth control while in the study, until at least one m onth after the last study drug 
application. 
2. Assess concomitant medicat ion/therapy/procedures. 
3. Verify that the subject is not wearing makeup. In the event the subject is wearing make-up, 
the appointment may be rescheduled, or the su bject should be instruct ed to wash the face 
with a Gentle Skin Cleanser; wait for 30 minutes prior to beginning the evaluations. 
4. Evaluate acne using IGA scale on the face (see Section 8.2.1 ). 
5. Conduct the facial Lesion Counts (see Section 8.2.2). 
6. Determine if, in the opi[INVESTIGATOR_125362], the subject is stil l a candidate for oral 
isotretinoin (see Section 8.2.3). 
7. Perform the Local Tolerability Assessment (erythema, dryness, scaling, stinging/burning; see Section 8.4.1 ). 
8. Question subject about the occurrence of AEs a nd record all events as appropriate on the 
corresponding AE eCRF pages (see Section 8.4.2 ). 
9. Ask subject to complete the Subject Satisfaction Questionnaire (see  Section 8.5.4 ). 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228062] A ssessment of Acne Improvement form (see  Section 
8.5.2). 
13. Obtain photographs of facial acne (see Section 8.5.1 ).  
14. Collect returned Investiga tional Study Medications (u sed and unused) and perform 
accountability evaluations as described in Section 7.4 . Discuss any concerns with 
compliance and note discussion in source documentation.  
15. Complete the Study Exit Form. 
9.2 Additional Instructions for Subjects 
There are no dietary or activit y requirements; however, subjects should avoid excess sun 
exposure. Each subject will be given both or al and written instructions for use of 
investigational study drugs, cleanser, and moistu rizer according to protocol. Subjects will be 
instructed to bring their study medica tions to each visit as noted in Sections 9.1.2 – 9. 1.5. 
10.0 PLANNED STATISTICAL ANALYSES AND STATISTICAL 
CONSIDERATIONS 
10.1 Statistical Analysis Plan 
A Statistical Analysis Plan (SAP) will be developed and finalized prior to database lock. The SAP will contain detailed descriptions of data conventions and statistical procedures for executing the analyses that are specif ied in the trial protocol below.  
Any deviation(s) from the SAP will be described and justified in the clinical study report. 
CCI
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 47 of 102 
 10.3 Analysis Populations 
The Intent-to-Treat (ITT) Population consists of the entire population enrolled at baseline. All 
efficacy data will be analyzed for the ITT population. 
The Safety Population consists of the Intent-to-Treat population, after ex clusion of subjects who 
never took the treatment with certainty, based on monitoring report. All safety analyses will be 
summarized for the Safety Population. 
10.4 Statistical Analysis 
10.4.1 General Methods 
All efficacy variables will be summarized at each visit for the ITT Population. Categorical 
variables will be summarized by [CONTACT_878980] (N, %). 
Continuous variables will be summar ized using number of subjects, means, standard deviations, 
medians, minimums, and maximums for the data collected at each visit.  Confidence intervals 
(CI) will be presented as appropriate. All ev aluations (including CIs) will be reported for 
exploratory purposes and will be interpreted as  such. No formal statistical tests will be 
performed. 
10.4.[ADDRESS_1228063] disposition will be summarized with the number of subjects in each 
population, the number and percentage of subj ects who complete the study, along with the 
number and percentage of subjects who do not  complete the study for each discontinuation 
reason as specified on the eCRFs. 10.4.3 Efficacy Analysis 
[IP_ADDRESS] Primary Efficacy Endpoint 
The primary endpoint is the reduction in the numbe r of inflammatory lesions at Week 12, and is 
the change in the inflammatory lesion count fr om Baseline to Week 12. The reduction in lesion 
count will be summarized with descriptive statis tics. A 95% CI for the re duction in lesions will 
be presented.  
The data will be summarized as observed, w ith no imputation for missing values. A last 
observation carried forward (LOCF) approach will be used as a se nsitivity analysis. 
[IP_ADDRESS] Secondary Efficacy Endpoints 
Secondary efficacy endpoints are: 
 IGA Success Rate at Weeks 4, 8, and 12 
 Percent reduction in total, inflammatory, and non-inflammatory lesions at Weeks 4, 8, 
and 12 
 Number and percent of subjec ts who, in the opi[INVESTIGATOR_8598] e Investigator, are candidates 
for oral isotretinoin at Weeks 0, 4, 8, and 12 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 48 of 102 
  Reduction in number of total, inflammator y, and non-inflammatory lesions at Weeks 4, 8, 
and 12 
 Subject Assessment of Acne  Improvement at Week 12 
The IGA Success Rate is defined as the number and percent of subjects rated as Clear (Grade 0) 
or Almost Clear (Grade 1). It  will be summarized at Weeks 4, 8, and 12 with a 95% CI for the 
Success Rate.  
The reduction in lesion count (both percent and number of lesions) at Weeks 4, 8, and 12 will be 
summarized with descriptive statistics a nd a 95% CI for the reduction in lesions. 
The number and percent of subjects who are candida tes for oral isotretinoin will be summarized 
at Weeks 0, 4, 8, and 12, and a 95% CI will be provided. 
The Subject Assessment of Acne Improvement at  Week 12 will be summarized with counts and 
percentages for each category (ranging from 0 = Complete Improvement to 5 = Worse).   
All data will be summarized as observed with  no imputation for missing values. LOCF will be 
performed as a sensitivity analysis. 
A pharmaco-economic analysis will be performed. 
10.4.4 Safety Analysis 
[IP_ADDRESS] Study Drug Exposure 
Exposure to investigational study drugs and comp liance will be summarized using descriptive 
statistics.  
[IP_ADDRESS] Adverse Events 
AE terms will be coded using the Medical Dic tionary for Regulatory Activities (MedDRA). 
Treatment-emergent AEs are defined as any AE with onset or (worsening of a pre-existing 
condition) after the first dose of study drug throu gh the end of participation in the study. AEs 
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 49 of 102 
 with partial dates will be assessed using the availa ble date information to determine if treatment-
emergent. AEs with completely missing dates wi ll be assumed to be treatment-emergent.  
Incidence of treatment-emergent AEs will be  summarized by [CONTACT_11189] 
(SOC) and preferred term (PT) for the Safety Population. If a subject has more than one AE 
with same PT, the subject will be counted only once for that PT. Additional summary tables will 
be provided for AEs considered related to the study drug, and AEs leadin g to discontinuation. 
All AEs will be displa yed in data listings.  
[IP_ADDRESS] Local Tolerability 
The symptoms of local tolerability (erythem a, scaling, dryness and stinging/burning) will be 
summarized by [CONTACT_878981]. Scores range 
from 0 = None to 3 = Severe. 
[IP_ADDRESS] Previous and Concomitant Medications, Therapi[INVESTIGATOR_014], and Procedures 
Previous and concomitant medications will be coded according to the World Health 
Organization (WHO) Drug Dictionary. Prior medicat ions are defined as those ending prior to 
the first dose of investigati onal study drug. Concomitant medications are defined as those 
ongoing at the time of the first dose of study drug or started after the first dose.  
11.[ADDRESS_1228064] or Independent Ethics Committee 
This clinical trial protocol and all amendments  will be reviewed and approved by [CONTACT_878982]/IECs. 11.[ADDRESS_1228065] 
their origin in the Declar ation of Helsinki (1964; Appendix 14.7) and subsequent amendments, 
U.S. and international standard s of GCP (FDA regulations 21 CFR 312 for Investigational New 
Drug (IND) studies and F DA Guidance E6), and applicable re gulatory requirements. To ensure 
ethical conduct of this clinical study, Investig ators will be expected to  adhere to the basic 
principles in recognized guide lines such the Belmont Report and the International Ethical 
Guidelines for Biomedical Rese arch Involving Human Subjects.  
11.3 Informed Consent 
All subjects who participate in this clinical trial are required to be fully informed about the 
clinical trial in accordance with GCP guidelines, federal regulations, and HIPAA, and in 
accordance with local requirements. 
The ICF (which contains Photography Consent and HIPAA authorization) and the Assent 
approved by [CONTACT_2717]/IEC will be fully explained to the subject (or parent/legal representative, if 
applicable). 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228066]’s parent/legal 
representative when the subject is a minor, will sign and date the consent form(s). The 
Investigator is responsible for maintaining each subject’s consent form(s) in the Investigator’s 
site file and providing each subjec t, or the subject’s parent or le gal representative (for minors), 
with a copy of the signed and dated consent form(s). 
11.4 Contractual Requirements 
A contractual agreement will be signed between  the Sponsor/Contract Research Organization 
(CRO) and each Investigator/Institution. This doc ument will contain supplementary information, 
including financial terms, confid entiality, the clinical trial sche dule, third party responsibility, 
and publication rights. 12.0 REGULATORY/ADMINISTRATIVE PROC EDURES AND DOCUMENTATION 
12.1 Quality Assurance and Audits/Inspections 
The study will be conducted under the sponsorsh ip of Galderma in compliance with all 
applicable international and local regulatory requ irements and applicable ICH guidelines, and in 
accordance with the SOPs for clin ical trial conduct and monitori ng from Galderma and/or the 
CRO. 
Audits of clinical trial cent ers may be conducted by [CONTACT_1034]/CRO representatives, and 
inspection may be performed by [CONTACT_878983]/IECs before, 
during, or after the clinical trial.  The Investigator will allow and assist the CRO/Sponsor’s repres entatives, IRBs/IECs, and any 
regulatory agency to have direct access to al l requested clinical trial-related records. 
For the audits performed by, or on behalf of, Galderma auditors, audit certificate(s) will be 
provided by [CONTACT_154505]. 
12.[ADDRESS_1228067], the Investigator should not 
deviate from the clinical trial protocol or implement any changes without written approval from 
the Sponsor and prior review and documented appr oval/favorable opi[INVESTIGATOR_5698]/IEC of a 
protocol amendment. 
Changes that involve only logistic al or administrative changes to the clinical tria l protocol are 
authorized. The Investigator shou ld document and explain any devi ation from the clinical trial 
protocol. 
12.[ADDRESS_1228068] to the subjects, without having been subm itted to the FDA or any appropriate Regulatory 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 51 of 102 
 Authority for its review and ha ving obtained approval from the I RB/EC with responsibility for 
review and approval of the clinical trial. 
12.4 Data Collection and Electronic Case Report Forms (eCRFs) 
The Investigator must maintain al l required records for all subjects. Data for this clinical trial 
will be recorded in the subject’s source doc uments and on the eCRFs provided by [CONTACT_1034]. 
All data should be recorded on th e eCRFs completely and promptly. 
12.[ADDRESS_1228069] keep accurate separate reco rds (other than the CRFs) of all subject visits, 
being sure to include all pertin ent clinical trial-related inform ation. A statement should be made 
indicating that the subjects have  been included in this clinical  trial and have provided signed 
written Informed Consent and Assent to Partic ipate as applicable. All AEs must be thoroughly 
documented. 
Results of any diagnostic tests conducted during the clinical trial should al so be included in the 
source documentation. 
12.6 Study Initiation and Personnel Training 
An Investigator’s Meeting will be conducted. It is recommended that all Investigators, other 
Evaluators, study coordinators, or other applicable personnel attend. During this meeting, 
participants will be trained on the protocol, ICH-GCP, study-specific procedures, and eCRF 
completion. Site personnel are e xpected to attend the Investigat or Meeting and receive on-site 
training prior to participating in  the procedures and evaluations in this study. Each study center 
will have a training record as part of the site file and Trial Master File. 
Study initiation will be conducted for each study cente r prior to the enrollment of any subjects.  
The Investigator Meeting may serve as the initiation visit. In  the event the Primary Investigator 
does not attend the Investigator Meeting but si te personnel attend, the Investigator may be 
initiated and trained via telephone/WebEx. If a site is not represented at th e Investigator Meeting 
and no personnel are present, an on-si te initiation visit will be required. 
Clinical Research Associates (CRAs) and othe r applicable personnel wi ll be trained prior to 
study initiation to familiarize the CRAs with the disease, the Standard Operating Procedures 
(SOPs)/study procedures, the protocol, and other study-specific items. Team organization, 
communication, and operational issu es will also be discussed. 
An Investigator’s Site File wi ll be provided to each study center. 
12.[ADDRESS_1228070] of the clinical tria l will be closely monitored by [CONTACT_878984], ICH-GCP guidelines, and applicable 
SOPs/study procedures. 
The Investigator will allow the CRO/Sponsor’s re presentatives, to have direct access to all 
clinical trial records, eCRF s, corresponding subject medical  records, study medication 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 52 of 102 
 dispensing records, study medication storage area, clinical tr ial facilities, and any other 
documents considered source documentation. 
12.8 Data Management 
All data management procedures will be de tailed in a Data Management Plan (DMP). 
The DMP will describe the Clinical Data Manage ment System (CDMS) that will be used to 
collect data via EDC, and whethe r the data management activities  are performed internally or 
outsourced. Computerized edit checks and revi ew processes will be performed on an ongoing 
basis as outlined in the DMP until all data clarifications  are resolved. The data will be exported 
to be stored in SAS datasets. After all data cl arifications are resolved, coding is approved, and 
subject’s evaluability is determin ed, the database will be locked. 
12.9 Study Documentation and Retention of Records 
All pertinent data, samples, photographs, correspondence, and reports, the original or amended 
clinical trial protocol, and all other material re lating to the clinical trial will be maintained 
securely in Sponsor/CRO/Investig ator/Institution archives for the legally required duration for 
archiving. 
The Investigator/Institution should ma intain the essential clinical tr ial documents as specified in 
Section 8 of ICH-GCP, and according to th e applicable regulatory requirements. 
The Investigator/Institution should take measures to  prevent accidental or premature destruction 
of these documents. If the Principal Investigator [INVESTIGATOR_878956], relocates, or withdraws from  the responsibility of keepi[INVESTIGATOR_154493], cu stody must be transferred to a person who will 
accept the responsibility. The Sponsor/CRO must be  notified in writing of the name [CONTACT_80703]. 
12.[ADDRESS_1228071] Party coverage of Sponsor/CRO will be provided upon request.
 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228072] Dermatol  1979;73(5 Pt 2):395-513. 
2. Cunliffe WJ, Gould DJ. Prevalen ce of facial acne vulgaris in la te adolescence and in adults. 
Br Med J  1979;1(6171):1109- 1110. 
3. Usatine RP, Quan MA, Strick R. Acne vulgaris: a treatment update. Hosp Pract  
(1995) 1998;33(2):111-117, 121-124, 127. Review. 
4. Leyden JJ. New understandings of  the pathogenesis of acne. J Am Acad Dermatol 1995;32(5 
Pt 3):S15-S25. Review. 
5. Thiboutot D. Regulation of human sebaceous glands. J Invest Dermatol  2004;123(1):1-12. 
6. Pawin H, Beylot C, Chivot M et al. Phys iopathology of acne vulgari s: recent data, new 
understanding of the treatments. Eur J Dermatol  2004;14(1):4-12. Review. 
7. Leyden JJ. A review of the use of combinati on therapi[INVESTIGATOR_878957]. J 
Am Acad Dermatol  2003;49([ADDRESS_1228073]):S200-S210. 
8. Rademaker M. Adverse effects of isotreti noin: A retrospective review of 1743 patients 
started on isotretinoin. Australas J Dermatol 2010;51(4):248-253. 
11. Lester RS, Schachter GD, Light MJ. Isotretinoin and tetracycline in the management of 
severe nodulocystic acne. Int J Dermatol 1985;24(4):252-257. 
12. Gollnick HP, Graupe K, Zaumseil RP. Comparison of combined azelaic acid cream plus oral minocycline with oral isotretinoin in severe acne . Eur J Dermatol 2001;11(6):538-544. 
13. Oprica C, Emtestam L, Hagströmer L, Nord CE . Clinical and microbiological comparisons of 
isotretinoin vs. tetracycline in acne vulgaris. Acta Derm Venereol 2007;87(3):246-254. 
14. Rumsfield JA, West DP, Tse CS et al Isotre tinoin in severe, recalc itrant cystic acne: a 
review. Drug Intell Clin Pharm 1983;17(5):329-333. Review. 
15. Strauss JS, Leyden JJ, Lucky AW et al. A randomized trial of the efficacy of a new micronized formulation versus a standard formul ation of isotretinoin in patients with severe 
recalcitrant nodular acne. J Am Acad Dermatol 2001;45(2):187-195. 
16. Akman A, Durusoy C, Senturk M et al. Treatme nt of acne with interm ittent and conventional 
isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res 
2007;299(10):467-473. 
17. Newman MD, Bowe WP, Heughebaert C et al. Th erapeutic considerations for severe nodular 
acne. Am J Clin Dermatol 2011;12(1):7-14. 
18. Goldsmith LA, Bolognia JL, Callen JP et al. Ame
 rican Academy of Dermatology Consensus 
Conference on the safe optimal use of is otretinoin: summary and recommendations. J Am 
Acad Dermatol 2004;50(6):900-906. 
19. Strauss JS, Rapi[INVESTIGATOR_576886], Shalita JR et al. Isotre tinoin therapy for acne: results of a multicenter 
dose-response study. J Am Acad Dermatol 1984;10(3):490-496. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 54 of 102 
 20. Strauss JS, Krowchuk DP, Leyden JJ et al. Guide lines of care for acne vulgaris management. 
J Am Acad Dermatol 2007;56(4):651-663. 
21. Karadag AS, Ertugrul DT, Tutal E et al. Isotre tinoin influences pi[INVESTIGATOR_878958]. Acta Derm Venereol 2011;91(1):31-34. 
22. Madden WS, Landells ID, Poulin Y et al. Treat ment of acne vulgaris and prevention of acne 
scarring: Canadian consensus guidelines. J Cutan Med Surg  2000;(4 Supp 1):S2 to S13. 
21. Gollnick H, Schramm M. Topi[INVESTIGATOR_878959]. Dermatol  1998;196(1):119-125. 
22. Brogden RN, Goa KE. Adapalene: A review of  its pharmacological pr operties and clinical 
potential in the management of mild to moderate acne. Drugs  1997;53(3):511-519. 
23. Michel S, Jomard A, Demarchez M. Pharmacology of adapalene. Br J Dermatol 
1998;139(Suppl 52):3-7. 
24. Shroot B, Michel S. Pharmacology and chemistry of adapalene . J Am Acad Dermatol 1997; 
36(6 Pt 2): S96-S103. Review. 
25. Leyden JJ. Current issues in antimicrobi al therapy for the treatment of acne. J Eur Acad 
Dermatol Venereol  2001;[ADDRESS_1228074] 3:51-55. Review. 
26. Pariser DM, Westmoreland P, Morris A et al . Long-term safety and efficacy of a unique 
fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment 
of acne vulgaris. J Drugs Dermatol 2007;6(9):899- 905. 
27. Tan J, Gollnick HP, Loesche C et al. Synergistic efficacy of adapalene 0.1%-benzoyl 
peroxide 2.5% in the treatment of 3855 acne vulgaris patients. J Dermatolog Treat 
2011;22(4)197-205. Epub 2010 Jul 28.  
28. Thiboutot DM, Weiss J, Bucko A et al. Adapalene-BPO Study Group. Adapalene-benzoyl 
peroxide, a fixed-dose combination for the treatment of acne vulga ris: results of a 
multicenter, randomized doubl e-blind, controlled study. J Am Acad Dermatol 
2007;57(5):791-799. 
29. Gollnick HP, Draelos Z, Glenn MJ et al. Adapalene-BPO Study Group. Adapalene-benzoyl 
peroxide, a unique fixed-dose co mbination topi[INVESTIGATOR_878960]: a 
transatlantic, randomized, double-bli nd, controlled study in 1670 patients. Br J Dermatol 
2009; 161(5):1180-1189. 
30. Gold LS, Tan J, Cruz-Santana A et al . Adapalene-BPO Study Group. A North American 
study of adapalene-benzoyl peroxide comb ination gel in the treatment of acne. Cutis 2009; 
84(2):110-116. 
31. Feldman SR, Tan J, Poulin Y et al. The efficacy of adapalene- benzoyl peroxide combination 
increases with number of acne lesions J Am Acad Dermatol 2011;64(6):1085-1091. 
32. Gold LS, Cruz A, Eichenfield L et al. Effec tive and safe combination therapy for severe acne 
vulgaris: a randomized, vehicle-controlled, double blind study of adapalene 0.1%-benzoyl 
peroxide 2.5% fixed-dose combination gel with doxycycline hyclate 100 mg. Cutis 
2010;85(2):94-104. 
33. Plewig G, Kligman AM. Acne and Rosacea, 3rd ed. [LOCATION_001]:Springer-Verlag; 2000. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 55 of 102 
 34. Webster GF, Leyden JJ. Suppression of pol ymorphonuclear leukocyte chemotactic factor 
production in Propi[INVESTIGATOR_878961], ampi[INVESTIGATOR_10312], minocycline, and erythromycin. Antimicrob Agents Chemother 
1982;21(5):770-772. 
35. Melski JW, Arndt KA. Current co ncepts: topi[INVESTIGATOR_878962]. N Engl J Med 
1980;302(9):503-506. 
36. Gollnick H, Cunliffe W, Be rson D et al. Management of  acne: a report from a Global 
Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003;49([ADDRESS_1228075]):S1-S37. 
37. Hanifin JM, Cooper KD, Ho VC et al. Guidelin es of care for atopic dermatitis, developed in 
accordance with the Am erican Academy of Dermatology (AAD)/American Academy of 
Dermatology Association “Adminis trative Regulations for Eviden ce-Based Clin ical Practice 
Guidelines.” J Am Acad Dermatol 2004;50(3):391-404. Erratum in: J Am Acad Dermatol 
2005;52(1):156. 
38. U.S. Department of Health and Human Serv ices Food and Drug Admi nistration, Center for 
Drug Evaluation and Research (CDER). Guidance for Industry, Acne Vulgaris: Developi[INVESTIGATOR_97209].  September 2005. 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 56 of 102 
 14.0 APPENDICES 
14.1 PACKAGE INSERTS FOR ADAPALENE 0.3% / BENZOYL PEROXIDE 2.5% 
GEL AND DOXYC YCLINE HYCLATE TABLETS 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 57 of 102 
 Package Insert for ADAPALENE 0.3 % / BENZOYL PEROXIDE 2.5% GEL 
 
 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 58 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 59 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
Final Date: 28 Jun 2016 Page 60 of 102 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 61 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 62 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 63 of 102 
   

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 64 of 102 
  
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 65 of 102 
  
 
    
 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 66 of 102 
 Package Insert for DOXYCYC LINE HYCLATE TABLETS  
 
 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 67 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 68 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 69 of 102 
   
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 70 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 71 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 72 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 73 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 74 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 75 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 76 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 77 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 78 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 79 of 102 
   

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 80 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 81 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 82 of 102 
   

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 83 of 102 
  
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 84 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 85 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 86 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 87 of 102 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228076] subjects to attend with a cl ean face and no make-up (f oundation, powder, concealer, blush), or remove 
makeup completely with Cetaphil® Gentle Skin Cleanser as soon as they arrive, and wait for 30 minutes prior to 
beginning assessments. Let the skin color return to normal before counting. 
3. Always use a lamp (and glasses, if needed), but do not routinely use a magnifying lens. Use the same room and 
constant lighting conditions for every evaluation. Avoid shadows. 
4. Position the subject in the same place every time. Make sure the subject is comfortable. The subject’s seat 
should be fairly high, so that the evaluator can view the facial skin comfortably (without excessive bending). 
5. Each subject should be assessed at all visits by [CONTACT_22960] (I nvestigator or designee): 
• Practice: count-recount (minimizes intra-rater variability). 
• Make your decision promptly - hesitation leads to confusion. 
• Evaluate the subject after visual inspection and palpation of the skin. Use palpation to assess the depth of 
the spots and to locate ones that are not obvious. 
• Do not stretch the skin; this alters the profile of the spots. 
• Where many lesions are present, stroke the skin from left to right or from top to bottom to avoid counting some spots more than once and others not at all. 
• Count the different types of lesions separately. Spots of any size should be counted, however small. 
• If it appears difficult to count accurately in a particul ar area, make a note and exclude this region every 
time for a given subject. If stubble is very obvious, it is best to avoid counting in the beard area. 
• Record any problems and how they were  dealt with in the subject’s notes. 
6. Lesions should routinely be counted on the whole face, area by [CONTACT_37264]:  
• The face is defined by [CONTACT_878985] (mandibular lines). 
• Use the following template to divide the face into five  areas to be evaluated: forehead, right cheek, left 
cheek, chin, and nose (see CRF). 
• Nodules/cysts are counted only at Screening/Baseline visit. 
 
 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228077] number of each lesion should be recorded on the appropriate CRF page. The lesion counts will be 
electronically added together to obtain a total lesion count. 
 
The following definitions describe the lesions to be counted: 
 Non-inflammatory lesions 
- Open Comedone - A mass of sebaceous material that  is impacted behind an  open follicular orifice 
(blackhead). 
- Closed Comedone - A mass of sebaceous material that is impacted behind a closed follicular orifice 
(white head). 
 Inflammatory lesions 
- Papules - A small, solid, red elevation less than [ADDRESS_1228078] of the le sion is above the surface 
of the skin. 
- Pustules - A small, circumscribed red elevation of the skin which contains yellow-white exudates. 
Nodules/Cysts, defined as circumscribed, elevated, solid lesions generally more than 1 cm in diameter with 
palpable depth, are counted at the Screening/Baseline vi sit only. No more than 2 nodules/cysts will be allowed 
for study participation (Exclusion Criterion #2, Section 6.2.2 ). Nodules/Cysts are not counted at post-Baseline 
visits.  
 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
Final Date: 28 Jun 2016  Page 92 of 102 
  
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: [ADDRESS_1228079] SATISFACTION QUESTIONNAIRE 
INSTRUCTIONS : 
Please complete this questionnaire regarding the study treatments you have been using in this study.  
Your answers will help us to better understand your needs and expectations.  
This questionnaire has been designed so that it can be completed quickly and easily. Please use black pen to 
complete this questionnaire. Please gi ve only ONE answer per question. 
There are no “Right” or “Wrong” answers.  
If you are unsure how to answer a question,  please give the best answer you can.  
If you need to make a change, draw a line through the answ er you would like to change, record your new response 
with a checkmark, and put your initials and today’s date next to your correction. 
Your answers will not affect your participation in the study and no prejudice will be shown towards you for 
completing this document. 
1. How bothered were you by [CONTACT_878986]? 
[  ]1 Not bothered at all 
[  ]2 Bothered somewhat 
[  ]3 Bothered 
[  ]4 Bothered a great deal 
2. How satisfied were you with the tim e it took for treatment to work? 
[  ]1 Very satisfied 
[  ]2 Satisfied 
[  ]3 Somewhat satisfied 
[  ]4 Not satisfied 
3. How satisfied were you with the effectiveness of the treatment? 
[  ]1 Very satisfied 
[  ]2 Satisfied 
[  ]3 Somewhat satisfied 
[  ]4 Not satisfied 
 

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 95 of 102 
 4. How do you feel about yourself, since starting your treatment? 
[  ]1 Very much better 
[  ]2 A lot better 
[  ]3 A little better 
[  ]4 Worse 
5. Overall, are you satisfied  with the treatment? 
[  ]1 Very satisfied 
[  ]2 Satisfied 
[  ]3 Somewhat satisfied 
[  ]4 Not satisfied 
6. Would you consider using this treatment again? 
[  ]1 Yes 
[  ]2 No 
7. Did you use the provided moisturizing lotion? 
[  ]1 Yes 
[  ]2 No 
a. If yes, would you say (check as many answers as you wish) 
[  ]1 The moisturizer helps to reduce irritation 
[  ]2 The moisturizer helps you to  be adherent to study 
treatments 
[  ]3 The moisturizer was pleasant to use 
[  ]4 None of the above 
 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
Final Date: 28 Jun 2016  Page 96 of 102 
  
     
 
   
 
 
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
Final Date: 28 Jun 2016  Page 97 of 102 
  
 
 
  
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
Final Date: 28 Jun 2016  Page 98 of 102 
   
CCI
Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 99 of 102 
 14.7 DECLARATION OF HELSINKI 
 
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 100 of 102 
  
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016   Page 101 of 102 
  
  

Galderma Laboratories, LP 
Protocol No.:  GLI.04.SPR.US10355 
 
Final Date: 28 Jun 2016  Page 102 of 102 
  
 
